# Grifols, S.A.

Annual Accounts 31 December 2014

Directors' Report 2014

(With Auditors' Report Thereon)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)



KPMG Auditores, S.L. Torre Realia Plaça d'Europa, 41 08908 L'Hospitalet de Llobregat Barcelona

## Independent Auditor's Report on the Annual Accounts

(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

To the Shareholders of Grifols, S.A.

## Report on the annual accounts

We have audited the accompanying annual accounts of Grifols, S.A. (the "Company"), which comprise the balance sheet at 31 December 2014, the income statement, statement of changes in equity and statement of cash flows for the year then ended, and notes.

## Directors' responsibility for the annual accounts

The Directors are responsible for the preparation of the accompanying annual accounts in such a way that they present fairly the equity, financial position and financial performance of Grifols, S.A., in accordance with the financial reporting framework applicable to the entity in Spain, specified in note 2 to the accompanying annual accounts, and for such internal control that they determine is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

## Auditor's responsibility

Our responsibility is to express an opinion on these annual accounts based on our audit. We conducted our audit in accordance with prevailing legislation regulating the audit of accounts in Spain. This legislation requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the annual accounts are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the annual accounts. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the annual accounts, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the annual accounts in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the annual accounts taken as a whole.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

KPMG Auditores S.L., a limited liability Spanish company and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"): a Swiss entity.

Reg. Mer Madrid, T. 11.961, F.90, Sec. 8, H. M -188.007, Inscrip. 9 N.I.F. B-78510153

## Opinion

In our opinion, the accompanying annual accounts present fairly, in all material respects, the equity and financial position of Grifols, S.A. at 31 December 2014, its financial performance and its cash flows for the year then ended in accordance with the applicable financial reporting framework and, in particular, with the accounting principles and criteria set forth therein.

## Report on other legal and regulatory requirements

The accompanying directors' report for 2014 contains such explanations as the Directors consider relevant to the situation of the Company, its business performance and other matters, and is not an integral part of the annual accounts. We have verified that the accounting information contained therein is consistent with that disclosed in the annual accounts for 2014. Our work as auditors is limited to the verification of the directors' report within the scope described in this paragraph and does not include a review of information other than that obtained from the accounting records of the Company.

KPMG Auditores, S.L.

(Signed on the original in Spanish)

Bernardo Rücker-Embden 23 February 2015

Annual Accounts and Directors' Report

31 December 2014

(With Auditor's Report Thereon)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanishlanguage version prevails)

## **Balance Sheets**

#### 31 December 2014 and 2013

## (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)

Intangible assets         Note 5         8,905,919         5,220,249           Computer software         6,163,117         5,138,119           Greenhouse gas emission allowances         2,619,946         -           Property, plant and equipment         Note 6         12,8265         8,2130           Technical installations, machinery, equipment, furniture and other items         11,528,431         9,992,831           Under construction and advances         11,123,86         5,027,906           Investment property         Note 7         72,509,791         4,946,480           Buildings         30,439,722         12,164,831,810         30,439,722           Land         37,225,871         3,410,074         16,58,242,265         1,329,475,204           Loans to companies         Note 14         16,410,455         18,155,520           Non-current investments         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,53,910         1,365,933           Raw materials and other supplies         Note 14         8,564,235         43,469,776           Trade receivables - current         365,051         824,198         366,235         3	Assets	Note	2014	2013
Computer software Greenhouse gas emission allowances Advances         6,163,117         5,138,119           Property, plant and equipment Technical installations, machinery, equipment, furniture and other items         Note 6         12,2636         82,130           Under construction and advances         1,152,8431         9,992,831         9,992,831           Under construction and advances         1,112,386         5,027,906           Investment property         Note 7         45,334,746         30,433,722           Land         29,099,084         22,137,168         5,027,906           Buildings         advances         3,725,871         3,410,074           Non-current investments in Group companies and associates         1,658,242,265         13,294,475,204           Equity instruments         Note 14         4,133,928         3,712,235           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Note 16         3,724,293         1,055,933           Work in progress – short cycle         20,032         100,272         2,036,650,51         824,198	Intangible assets	Note 5	8.905.919	5.220.249
Greenhouse gas emission allowances Advances         122,856         82,130           Advances         2,619,946         2,619,946           Property, plant and equipment other items         11,528,431         9,992,831           Under construction and advances         1,112,386         5,027,906           Investment property         Note 7         45,334,746         30,493,722           Land         29,099,084         22,137,168         3,722,5871         3,410,074           Non-current investments in Group companies and associates         1,658,242,265         1,329,475,204         1,641,831,810         1,311,316,684           Loans to companies         Note 12         1,641,831,810         1,311,316,684         1,312,325           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         1,346,719,456         1,326,719,456           Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         270,032         100,272           Work in progress – short cycle         270,032         100,272           Trade receivables from Group companies and associates – current tax assets         Note 25         32,517,642         11,925,808           Other receivables				
Advances         2.619.946         -           Property, plant and equipment Technical installations, machinery, equipment, furniture and other items         Note 6         12,640,817         15,020,737           Technical installations, machinery, equipment, furniture and other items         11,528,431         9,992,831           Under construction and advances         11,12.386         5,027,906           Investment property         Note 7         45,334,746         30,493,722           Land         22,099,084         22,137,168           Buildings         Note 7         12,560,871         3,410,074           Non-current investments in Group companies and associates         16,58,242,265         1,329,475,204           Construct investments         Note 14         16,410,455         18,158,520           Non-current investments         Note 14         4,133,928         3,712,235           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Inventories         Note 14         4,133,928         3,712,235           Raw materials and other supplies         Note 14         365,051         955,661           Work in progress – short cycle         11,427,335         2,210,983				
Property, plant and equipment other items         Note 6         12,640,817         15,020,737           Technical installations, machinery, equipment, furniture and other items         11,528,431         9,992,831           Under construction and advances         11,123,866         5,027,906           Investment property         Note 7         45,334,746         30,493,722           Land         12,509,791         4,946,480           Buildings         1,058,242,265         1,329,475,204           Equity instruments         Note 14         16,610,452         1,112,386           Loans to companies         Note 14         16,410,455         18,158,520           Other financial assets         Note 14         14,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 16         3,724,293         1,055,933           Raw materials and other supplies         3464,261         955,661         927,032         100,272           Trade receivables - current         366,051         824,198         68,284 <td< th=""><th></th><th></th><th></th><th>-</th></td<>				-
Technical installations, machinery, equipment, furniture and other items       11,528,431       9,992,831         Under construction and advances       1,112,386       5,027,906         Investment property Land       Note 7       45,334,746       30,493,722         Land       22,099,084       22,137,168         Buildings       12,509,791       4,946,480         Investments in adaptation and advances       16,552,791       4,946,480         Non-current investments in Group companies and associates       16,542,265       1,329,475,204         Equity instruments       Note 14       16,410,455       18,158,520         Other financial assets       Note 14       4,133,928       3,712,235         Other financial assets       Note 14       4,133,928       3,712,235         Deferred tax assets       Note 14       4,133,928       3,712,235         Inventories       Note 16       3,724,293       1,055,933         Raw materials and other supplies       Note 16       3,724,293       1,055,933         Work in progress – short cycle       270,032       100,272       100,272         Trade receivables – current       365,051       824,198       11,410       8,827         Current twestments in Group companies and associates – current       Note 23	Property, plant and equipment	Note 6		15,020,737
Under construction and advances       1,112,386       5,027,906         Investment property       Land       30,493,722         Land       1,2509,791       4,946,480         Buildings       29,099,084       22,137,168         Investments in adaptation and advances       3,725,871       3,410,074         Non-current investments in Group companies and associates       1,641,831,810       1,311,316,684         Loans to companies       Note 14       1,641,831,810       1,311,316,684         Loans to companies       Note 14       4,133,928       3,712,235         Other financial assets       Note 14       4,133,928       3,712,235         Deferred tax assets       Note 14       4,133,928       3,712,235         Inventories       Note 14       4,133,928       3,712,235         Raw materials and other supplies       Note 14       85,504,235       43,469,776         Trade receivables - current       3466,261       955,661       824,198         Trade receivables from Group companies and associ	Technical installations, machinery, equipment, furniture and			
Investment property Land         Note 7         45,334,746 (2,509,791)         30,493,722 (2,509,791)           Land         29,099,084         22,137,168           Buildings         3,725,871         3,410,074           Investments in adaptation and advances         3,725,871         3,410,074           Non-current investments in Group companies and associates         1,658,242,265         1,329,475,204           Equity instruments         Note 12         1,641,831,810         1,311,316,684           Loans to companies         Note 14         1,641,831,801         1,311,316,684           Loans to companies         Note 14         4,133,928         3,712,235           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 23         11,427,335         2,797,309           Total non-current assets         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Note 14         85,504,235         43,469,776           Work in progress – short cycle         270,032         100,272           Trade receivables from Group companies and associates – current         Note 23         43,469,776           Other receivables from Group companies and associates – current investinents in Group companies and associates	other items		11,528,431	9,992,831
Land       12,509,791       4,946,480         Buildings       1,658,242,265       1,329,475,204         Investments in adaptation and advances       Note 12       1,641,831,810       1,311,316,684         Loans to companies       Note 14       1,641,831,810       1,311,316,684         Loans to companies       Note 14       4,133,928       3,712,235         Other financial assets       Note 14       4,133,928       3,712,235         Deferred tax assets       Note 14       4,133,928       3,712,235         Deferred tax assets       Note 14       4,133,928       3,712,235         Raw materials and other supplies       Note 14       3,454,261       955,661         Inventories       Note 16       3,724,293       1,055,933         Raw materials and other supplies       Note 14       85,504,235       43,469,776         Trade receivables – current       Trade receivables       Note 14       85,504,235       43,469,776         Trade receivables – current       Note 23       5,51,7642       11,925,808       68,284       631,923         Other receivables       Note 23       47,190,583       22,340,496       11,410       8,827         Public entities, other       Note 23       5,51,265       7,73,524	Under construction and advances		1,112,386	5,027,906
Buildings Investments in adaptation and advances         29,099,084         22,137,168           Non-current investments in Group companies and associates         3,725,871         3,410,074           Loans to companies         Note 12         1,658,242,251         1,329,475,204           Non-current investments         Note 14         1,641,831,810         1,311,316,684           Loans to companies         Note 14         1,641,831,810         1,311,316,684           Non-current investments         Note 14         4,133,928         3,712,235           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 13         1,447,335         2,797,309           Total non-current assets         1,740,685,010         1,386,719,456           Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Vork in progress – short cycle         270,032         100,272           Trade receivables         rade receivables         Note 14         85,504,235         43,469,776           Trade receivables from Group companies and associates – current         S66,24         631,923         11,410         8,827           Qurrent tax assets         Note 23         47,190,583         22,340,496	Investment property	Note 7	45,334,746	30,493,722
Investments in adaptation and advances         3,725,871         3,410,074           Non-current investments in Group companies and associates         1,658,242,265         1,329,475,204           Equity instruments         Note 14         1,641,831,810         1,311,316,684           Loans to companies         Note 14         1,641,831,810         1,311,316,684           Non-current investments         Note 14         4,133,928         3,712,235           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 23         11,427,335         2,797,309           Total non-current assets         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Note 16         3,724,235         14,641,945           Work in progress – short cycle         270,032         100,272         100,272           Trade and other receivables         Note 14         85,504,235         43,469,776           Trade receivables from Group companies and associates – current         366,051         824,198           Trade receivables         Note 23         5,351,265         7,738,524           Public entities, other         Note 23         5,351,265         7,738,524           Current tax assets         Note 14<	Land			
Non-current investments in Group companies and associates Equity instruments         Note 12 1,641,831,810         1,329,475,204           Equity instruments         Note 12         1,641,831,810         1,311,316,684           Loans to companies         Note 14         1,641,831,810         1,311,316,684           Non-current investments         Note 14         4,133,928         3,712,235           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 23         11,427,335         2,797,309           Total non-current assets         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Note 16         3,724,293         1,055,933           Work in progress – short cycle         270,032         100,272           Trade and other receivables         Note 14         85,504,235         43,469,776           Trade receivables – current         Note 25         32,517,642         11,925,808           Other receivables from Group companies and associates – current tax assets         Note 23         5,351,265         7,738,524           Purblic entities, other         Note 23         5,351,265         7,738,524,409,563         22,340,496           Current investments in Group companies and associates         Note 14	0			22,137,168
Equity instruments Loans to companies         Note 12 Nor-current investments         Note 14 Note 14 (16,410,455         1,311,316,684 (16,410,455           Non-current investments Other financial assets         Note 14 (4,133,928         1,312,235           Deferred tax assets         Note 23         1,427,335         2,797,309           Total non-current assets         1,740,685,010         1,386,719,456           Inventories Raw materials and other supplies Work in progress – short cycle         1,740,685,010         1,366,719,456           Trade and other receivables Current         Note 16         3,724,293         1,055,933           Trade receivables – current Trade receivables from Group companies and associates – current         Note 14         85,504,235         43,469,776           Trade receivables from Group companies and associates – current tax assets         Note 23         3,2517,642         11,925,808           Other receivables Personnel         Note 23         47,190,583         22,304,466         8,827           Current investments in Group companies and associates Loans to companies         Note 14         8,802         15,573           Other financial assets         Note 14         8,802         15,573           Other financial assets         Note 14         8,802         15,573           Other financial assets         Note 17         8,802<				, ,
Loans to companies         Note 14         16,410,455         18,158,520           Non-current investments         Note 14         4,133,928         3,712,235           Other financial assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 23         11,427,335         2,797,309           Total non-current assets         1,740,685,010         1,386,719,456           Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         0         3,454,261         955,661           Work in progress – short cycle         270,032         100,272           Trade and other receivables         nor Group companies and associates – current         365,051         824,198           Trade receivables – current         365,051         824,198         11,410         8,827           Current investiments in Group companies and associates – current investiments in Group companies and associates         Note 23         5,351,265         7,738,524           Current investiments in Group companies and associates         Note 14         8,802         15,573           Deferred tax assets         Note 14         8,802         15,573           Current investiments in Group companies and associates         Note 14         8,802				
Non-current investments Other financial assets         Note 14 Note 14         Note 14 4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 14         4,133,928         3,712,235           Deferred tax assets         Note 23         11,427,335         2,797,309           Total non-current assets         1,740,685,010         1,386,719,456           Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Work in progress – short cycle         270,032         100,272           Trade and other receivables         Current         365,051         824,198           Trade receivables from Group companies and associates – current         Note 25         32,517,642         11,925,808           Other receivables         68,284         631,923         14,410         8,827           Current tax assets         Note 23         47,190,583         22,340,496           Public entities, other         Note 23         5,351,265         7,738,524           Current investments in Group companies and associates         Note 14         8,802         15,573				
Other financial assets         Note 14 Note 23         4,133,928 11,427,335         3,712,235 2,797,309           Total non-current assets         1,740,685,010         1,386,719,456           Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Note 16         3,724,293         1,055,933           Work in progress – short cycle         270,032         100,272           Trade receivables         Note 14         85,504,235         43,469,776           Trade receivables – current         Note 25         32,517,642         11,925,808           Other receivables from Group companies and associates – current         Note 25         32,517,642         11,925,808           Other receivables         Note 23         47,190,583         22,340,496         68,284         631,923           Personnel         Note 23         5,351,265         7,738,524         7,738,524           Current investments in Group companies and associates         Note 14         8,802         15,573           Prepayments for current assets         Note 14         8,802         15,573           Prepayments for current assets         Note 17         4,891,351         2,847,802           Cash and cash equivalents         23,505,652         110,536,215         <				
Deferred tax assets         Note 23         11,427,335         2,797,309           Total non-current assets         1,740,685,010         1,386,719,456           Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         3,454,261         955,661           Work in progress – short cycle         270,032         100,272           Trade and other receivables         Note 14         85,504,235         43,469,776           Trade receivables – current         365,051         824,198         84,198           Trade receivables from Group companies and associates – current         Note 25         32,517,642         11,925,808           Other receivables         68,284         631,923         11,410         8,827           Personnel         11,410         8,827         11,410         8,827           Current tax assets         Note 23         5,351,265         7,738,524           Current investments in Group companies and associates         Note 14         8,802         15,573           Loans to companies         222,110,583         538,787,935         222,110,583         538,787,935           Loans to current assets         Note 14         8,802         15,573         8,802         15,573 <td< th=""><th></th><th></th><th></th><th></th></td<>				
Total non-current assets         Note 16         1,740,685,010         1,386,719,456           Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         Work in progress – short cycle         270,032         100,272           Trade and other receivables         current         3,454,261         955,661           Trade receivables – current         365,051         824,198           Trade receivables – current         365,051         824,198           Trade receivables – current         365,051         824,198           Current         Note 25         32,517,642         11,925,808           Other receivables         68,284         631,923         1,1410         8,827           Current tax assets         Note 23         47,190,583         22,340,496           Public entities, other         Note 23         5,351,265         7,738,524           Current investments in Group companies and associates         Note 14         8,802         15,573           Current investments         Note 14         8,802         15,573           Prepayments for current assets         Note 17         4,891,351         2,847,802           Cash and cash equivalents         23,505,652         110,536,215         23,505,652 <th></th> <th></th> <th></th> <th></th>				
Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         3,454,261         955,661           Work in progress – short cycle         270,032         100,272           Trade and other receivables         Note 14         85,504,235         43,469,776           Trade receivables – current         365,051         824,198         365,051         824,198           Trade receivables from Group companies and associates – current         Note 25         32,517,642         11,925,808           Other receivables         68,284         631,923         11,410         8,827           Current tax assets         Note 23         47,190,583         22,340,496           Public entities, other         Note 23         5,351,265         7,738,524           Current investments in Group companies and associates         Note 14         222,110,583         538,787,935           Loans to companies         Current investments         S38,787,935         222,110,583         538,787,935           Current investments         Other financial assets         Note 14         8,802         15,573           Prepayments for current assets         Note 17         4,891,351         2,847,802         23,505,652         110,536,215           Cash <td< th=""><th>Deferred tax assets</th><th>Note 23</th><th>11,427,335</th><th>2,797,309</th></td<>	Deferred tax assets	Note 23	11,427,335	2,797,309
Inventories         Note 16         3,724,293         1,055,933           Raw materials and other supplies         3,454,261         955,661           Work in progress – short cycle         270,032         100,272           Trade and other receivables         Note 14         85,504,235         43,469,776           Trade receivables – current         365,051         824,198         365,051         824,198           Trade receivables from Group companies and associates – current         Note 25         32,517,642         11,925,808           Other receivables         68,284         631,923         11,410         8,827           Current tax assets         Note 23         47,190,583         22,340,496           Public entities, other         Note 23         5,351,265         7,738,524           Current investments in Group companies and associates         Note 14         222,110,583         538,787,935           Loans to companies         Current investments         S38,787,935         222,110,583         538,787,935           Current investments         Other financial assets         Note 14         8,802         15,573           Prepayments for current assets         Note 17         4,891,351         2,847,802         23,505,652         110,536,215           Cash <td< th=""><th>Total non-current assets</th><th></th><th>1,740,685,010</th><th>1,386,719,456</th></td<>	Total non-current assets		1,740,685,010	1,386,719,456
Raw materials and other supplies       3,454,261       955,661         Work in progress – short cycle       270,032       100,272         Trade and other receivables       Note 14       85,504,235       43,469,776         Trade receivables – current       365,051       824,198         Trade receivables from Group companies and associates – current       Note 25       32,517,642       11,925,808         Other receivables       68,284       631,923       68,284       631,923         Personnel       11,410       8,827       11,410       8,827         Current tax assets       Note 23       5,351,265       7,738,524         Public entities, other       Note 23       5,351,265       7,738,524         Current investments in Group companies and associates       Note 14       8,802       15,573         Loans to companies       222,110,583       538,787,935       222,110,583       538,787,935         Current investments       Note 14       8,802       15,573       0ther financial assets       8,802       15,573         Prepayments for current assets       Note 17       4,891,351       2,847,802       10,536,215         Cash       339,744,916       696,713,234       23,505,652       110,536,215				· · · · · · · · · · · · · · · · · · ·
Work in progress – short cycle       270,032       100,272         Trade and other receivables       Note 14       85,504,235       43,469,776         Trade receivables – current       365,051       824,198         Trade receivables from Group companies and associates – current       Note 25       32,517,642       11,925,808         Other receivables       68,284       631,923       11,410       8,827         Current tax assets       Note 23       47,190,583       22,340,496         Public entities, other       Note 23       5,351,265       7,738,524         Current investments in Group companies and associates       Note 14       222,110,583       538,787,935         Loans to companies       Note 14       8,802       15,573         Other financial assets       Note 14       8,802       15,573         Prepayments for current assets       Note 14       8,802       15,573         Cash       Cash       339,744,916       696,713,234	Inventories	Note 16		1,055,933
Trade and other receivables       Note 14       85,504,235       43,469,776         Trade receivables – current       365,051       824,198         Trade receivables from Group companies and associates – current       Note 25       32,517,642       11,925,808         Other receivables       68,284       631,923       11,410       8,827         Current tax assets       Note 23       47,190,583       22,340,496         Public entities, other       Note 23       5,351,265       7,738,524         Current investments in Group companies and associates       Note 14       222,110,583       538,787,935         Loans to companies       Note 14       8,802       15,573         Current investments       Note 14       8,802       15,573         Other financial assets       Note 14       8,802       15,573         Prepayments for current assets       Note 17       4,891,351       2,847,802         Cash and cash equivalents       23,505,652       110,536,215       23,505,652       110,536,215         Cash       339,744,916       696,713,234       339,744,916       696,713,234			3,454,261	955,661
Trade receivables - current365,051824,198Trade receivables from Group companies and associates - currentNote 2532,517,64211,925,808Other receivables68,284631,923Personnel11,4108,827Current tax assetsNote 2347,190,58322,340,496Public entities, otherNote 235,351,2657,738,524Current investments in Group companies and associatesNote 14222,110,583538,787,935Loans to companies222,110,583538,787,935222,110,583538,787,935Current investmentsNote 148,80215,573Other financial assetsNote 174,891,3512,847,802Cash and cash equivalents Cash23,505,652110,536,215Cash339,744,916696,713,234				
Trade receivables from Group companies and associates – currentNote 2532,517,64211,925,808Other receivables68,284631,923Personnel11,4108,827Current tax assetsNote 2347,190,58322,340,496Public entities, otherNote 235,351,2657,738,524Current investments in Group companies and associatesNote 14222,110,583538,787,935Loans to companiesNote 148,80215,573Current investmentsNote 148,80215,573Other financial assetsNote 174,891,3512,847,802Prepayments for current assetsNote 174,891,3512,847,802Cash and cash equivalents Cash23,505,652110,536,21523,505,652110,536,215Cash339,744,916696,713,234		Note 14		
current       Note 25       32,517,642       11,925,808         Other receivables       68,284       631,923         Personnel       11,410       8,827         Current tax assets       Note 23       47,190,583       22,340,496         Public entities, other       Note 23       5,351,265       7,738,524         Current investments in Group companies and associates       Note 14       222,110,583       538,787,935         Loans to companies       222,110,583       538,787,935       538,787,935         Current investments       Note 14       8,802       15,573         Other financial assets       Note 14       8,802       15,573         Prepayments for current assets       Note 17       4,891,351       2,847,802         Cash and cash equivalents       23,505,652       110,536,215       23,505,652       110,536,215         Cash       339,744,916       696,713,234       696,713,234			365,051	824,198
Other receivables       68,284       631,923         Personnel       11,410       8,827         Current tax assets       Note 23       47,190,583       22,340,496         Public entities, other       Note 23       5,351,265       7,738,524         Current investments in Group companies and associates       Note 14       222,110,583       538,787,935         Loans to companies       Note 14       8,802       15,573         Current investments       Note 14       8,802       15,573         Other financial assets       Note 14       8,802       15,573         Prepayments for current assets       Note 17       4,891,351       2,847,802         Cash and cash equivalents       23,505,652       110,536,215       23,505,652       110,536,215         Cash       339,744,916       696,713,234       696,713,234	· ·			
Personnel11,4108,827Current tax assetsNote 2347,190,58322,340,496Public entities, otherNote 235,351,2657,738,524Current investments in Group companies and associatesNote 14222,110,583538,787,935Loans to companiesNote 148,80215,573Current investmentsNote 148,80215,573Other financial assetsNote 174,891,3512,847,802Cash and cash equivalents23,505,652110,536,21523,505,652Cash339,744,916696,713,234		Note 25	32.517.642	11.925.808
Current tax assets Public entities, otherNote 23 Public entities, otherNote 23 Public entities, other47,190,583 Public entities, other22,340,496 Public entities, otherCurrent investments in Group companies and associates Loans to companiesNote 145,351,265 Public entities, other7,738,524 Public entities, otherCurrent investments Other financial assetsNote 14222,110,583 Prepayments for current assets538,787,935 Piter financial assets222,110,583 Piter financial assets538,787,935 Piter financial assets15,573 Piter financial assetsPrepayments for current assetsNote 148,802 Piter financial assets15,573 Piter financial assets10,536,215 Piter financial assetsCash and cash equivalents Cash23,505,652 Piter financial assets110,536,215 Piter financial assets339,744,916696,713,234	()ther receivables			
Public entities, otherNote 235,351,2657,738,524Current investments in Group companies and associatesNote 14222,110,583538,787,935Loans to companiesNote 14222,110,583538,787,935Current investmentsNote 148,80215,573Other financial assetsNote 148,80215,573Prepayments for current assetsNote 174,891,3512,847,802Cash and cash equivalents23,505,652110,536,215110,536,215Cash339,744,916696,713,234			68,284	631,923
Current investments in Group companies and associates         Note 14         222,110,583         538,787,935           Loans to companies         222,110,583         538,787,935         222,110,583         538,787,935           Current investments         Note 14         8,802         15,573           Other financial assets         8,802         15,573           Prepayments for current assets         Note 17         4,891,351         2,847,802           Cash and cash equivalents         23,505,652         110,536,215         23,505,652         110,536,215           Cash         339,744,916         696,713,234         696,713,234         696,713,234	Personnel	Nata 00	68,284 11,410	631,923 8,827
Loans to companies       222,110,583       538,787,935         Current investments       Note 14       8,802       15,573         Other financial assets       8,802       15,573       8,802       15,573         Prepayments for current assets       Note 17       4,891,351       2,847,802         Cash and cash equivalents       23,505,652       110,536,215       23,505,652       110,536,215         Cash       339,744,916       696,713,234       696,713,234	Personnel Current tax assets		68,284 11,410 47,190,583	631,923 8,827 22,340,496
Current investments         Note 14         8,802         15,573           Other financial assets         8,802         15,573           Prepayments for current assets         Note 17         4,891,351         2,847,802           Cash and cash equivalents         23,505,652         110,536,215           Cash         23,505,652         110,536,215           Total current assets         339,744,916         696,713,234	Personnel Current tax assets Public entities, other	Note 23	68,284 11,410 47,190,583 5,351,265	631,923 8,827 22,340,496 7,738,524
Other financial assets         8,802         15,573           Prepayments for current assets         Note 17         4,891,351         2,847,802           Cash and cash equivalents         23,505,652         110,536,215         23,505,652         110,536,215           Cash         339,744,916         696,713,234         696,713,234	Personnel Current tax assets Public entities, other Current investments in Group companies and associates	Note 23	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b>	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b>
Prepayments for current assets         Note 17         4,891,351         2,847,802           Cash and cash equivalents         23,505,652         110,536,215         23,505,652         110,536,215           Cash         23,505,652         110,536,215         23,505,652         110,536,215           Total current assets         339,744,916         696,713,234	Personnel Current tax assets Public entities, other <b>Current investments in Group companies and associates</b> Loans to companies	Note 23 Note 14	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b> 222,110,583	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b> 538,787,935
Cash and cash equivalents         23,505,652         110,536,215           Cash         23,505,652         110,536,215           Total current assets         339,744,916         696,713,234	Personnel Current tax assets Public entities, other Current investments in Group companies and associates Loans to companies Current investments	Note 23 Note 14	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b> 222,110,583 <b>8,802</b>	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b> 538,787,935 <b>15,573</b>
Cash         23,505,652         110,536,215           Total current assets         339,744,916         696,713,234	Personnel Current tax assets Public entities, other <b>Current investments in Group companies and associates</b> Loans to companies <b>Current investments</b> Other financial assets	Note 23 Note 14 Note 14	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b> 222,110,583 <b>8,802</b> 8,802	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b> 538,787,935 <b>15,573</b> 15,573
Total current assets 339,744,916 696,713,234	Personnel Current tax assets Public entities, other Current investments in Group companies and associates Loans to companies Current investments Other financial assets Prepayments for current assets	Note 23 Note 14 Note 14	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b> 222,110,583 <b>8,802</b> 8,802 <b>4,891,351</b>	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b> 538,787,935 <b>15,573</b> 15,573 <b>2,847,802</b>
	Personnel Current tax assets Public entities, other Current investments in Group companies and associates Loans to companies Current investments Other financial assets Prepayments for current assets Cash and cash equivalents	Note 23 Note 14 Note 14	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b> 222,110,583 <b>8,802</b> 8,802 <b>4,891,351</b> <b>23,505,652</b>	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b> 538,787,935 <b>15,573</b> 15,573 <b>2,847,802</b> <b>110,536,215</b>
	Personnel Current tax assets Public entities, other Current investments in Group companies and associates Loans to companies Current investments Other financial assets Prepayments for current assets Cash and cash equivalents	Note 23 Note 14 Note 14	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b> 222,110,583 <b>8,802</b> 8,802 <b>4,891,351</b> <b>23,505,652</b>	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b> 538,787,935 <b>15,573</b> 15,573 <b>2,847,802</b> <b>110,536,215</b>
Total assets 2,080,429,926 2,083,432,690	Personnel Current tax assets Public entities, other Current investments in Group companies and associates Loans to companies Current investments Other financial assets Prepayments for current assets Cash and cash equivalents Cash	Note 23 Note 14 Note 14	68,284 11,410 47,190,583 5,351,265 <b>222,110,583</b> 222,110,583 <b>8,802</b> 8,802 4,891,351 23,505,652 23,505,652	631,923 8,827 22,340,496 7,738,524 <b>538,787,935</b> 538,787,935 <b>15,573</b> 15,573 <b>2,847,802</b> <b>110,536,215</b> 110,536,215

## **Balance Sheets**

#### 31 December 2014 and 2013

## (Expressed in Euros)

Equity and Liabilities	Note	2014	2013
Capital and reserves	Note 18	1,284,378,496	1,304,440,552
Capital Registered capital		119,603,705	119,603,705
Share premium Reserves		910,727,619	910,727,619
Legal and statutory reserves		23,920,741	23,576,478
Other reserves (Treasury stock and equity holdings)		180,125,869 (69,252,443)	150,937,357 -
Profit for the year		205,197,369	168,350,884
(Interim dividend) Valuation adjustments		(85,944,364) -	(68,755,491) <b>(669,792)</b>
Hedging transactions	Note 15	-	(669,792)
Grants, donations and bequests received		79,542	74,239
Total equity		1,284,458,038	1,303,844,999
Non-current payables	Note 21	46,649,450	370,241,045
Loans and borrowings		14,211,247	332,229,183
Finance lease payables	Note 8	2,174,537	1,453,878
Derivatives	Note 15	-	7,563,959
Other financial liabilities Group companies and associates, non-current	Note 21	30,263,666 <b>409,536,410</b>	28,994,025 <b>86,201,597</b>
Deferred tax liabilities	Note 23	3,334,193	4,277,996
			<u>, , ,  </u>
Total non-current liabilities		459,520,053	460,720,638
Current provisions	Note 19	685,517	185,517
Other provisions		685,517	185,517
Current payables Loans and borrowings	Note 21	<b>6,761,698</b> 4,810,340	<b>39,422,872</b> 37,630,146
Finance lease payables	Note 8	949,505	946,209
Other financial liabilities	11010 0	1,001,853	846,517
Group companies and associates, current	Note 21	230,380,846	219,195,997
Trade and other payables	Note 21	98,623,774	60,062,667
Current payables to suppliers		33,751,144	42,907,308
Suppliers, Group companies and associates, current	Note 25	8,928,909	8,082,603
Personnel (salaries payable)		10,156,817	7,721,943
Current Income tax liabilities	Note 23	30,004,299	-
Public entities, other	NOLE 23	15,782,605	1,350,813
Total current liabilities		336,451,835	318,867,053
Total equity and liabilities		2,080,429,926	2,083,432,690

#### Income Statements for the years ended 31 December 2014 and 2013

#### (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)

	Note	2014	2013
Revenues	Note 26	375,610,748	312,669,570
Services rendered		90,615,939	85,589,288
Finance income	Note 13	13,309,791	4,387,719
Dividends		271,685,018	222,692,563
Changes in inventories of finished goods and work in progress		169,761	100,272
Self-constructed assets		1,347,339	1,471,953
Supplies	Note 26	(1,881,527)	(2,404,665)
Raw materials and consumables used		(1,017,671)	(617,986)
Subcontracted work		(857,352)	(1,739,310)
Impairment of merchandise, raw materials and other supplies		(6,504)	(47,369)
Other operating income		4,303,434	4,856,473
Non-trading and other operating income		4,193,826	4,782,858
Operating grants taken to income		109,608	73,615
Personnel expenses	Note 26	(41,298,739)	(36,082,101)
Salaries and wages		(34,639,951)	(30,636,478)
Employee benefits expense	Note 26		
Provisions	Note 20	(6,645,276)	(5,433,969)
Other operating expenses		(13,512)	(11,654)
External services		(90,088,840)	(101,420,374)
		(89,727,759)	(98,096,841)
Taxes		(221,337)	(205,445)
Losses, impairment and changes in trade provisions	Note 14	60F 260	(2 225 172)
Other operating expenses	NOLE 14	695,360	(2,335,173)
Amortisation and depreciation	Notes 5, 6	(835,104)	(782,915)
	and 7	(6,565,102)	(5,445,343)
Non-financial and other capital grants	Note 5	(0,000,102)	(21,256)
Impairment and gains/(losses) on disposal of fixed assets	Note 26	2,532,400	(4,980,297)
Impairment and losses	Note 12	2,860,145	(4,920,286)
Losses on disposal and other	Note 7	(327,745)	(4,020,200)
		(021,140)	(00,011)
Results from operating activities		244,129,474	168,744,232
Finance income		23,906	551,396
Other investment income			
Other	Note 13	45,870	387,701
Capitalised borrowing costs	Note 6	(21,964)	163,695
Finance costs	Note 20	(54,129,441)	(24,358,345)
Group companies and associates	Note 25	(27,445,636)	(749,465)
Third parties		(26,683,805)	(23,608,880)
Change in fair value of financial instruments	Notes 13 and		
	20	2,249,126	(758,407)
Trading portfolio and other		2,249,126	(281,924)
Proceeds from available-for-sale financial assets		-	(476,483)
Exchange gains/(losses)	Notes 14 and		
	21	(16,980,897)	6,778,600
Net finance cost		(68,837,306)	(17,786,756)
Profit before income tax		175,292,168	150,957,476
Income tax	Note 23	29,905,201	17,393,408
		,,	,, . <del>.</del>
Profit for the year		205,197,369	168,350,884

#### Statements of Changes in Equity for the years ended 31 December 2014 and 2013

#### A) Statements of Recognised Income and Expense for the years ended 31 December 2014 and 2013

#### (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)

	Note	2014	2013
Profit for the year		205,197,369	168,350,884
Income and expense recognised directly in equity			
Cash flow hedges Tax effect	Note 15	(333,033) 99,910	3,364,474 (1,009,342)
Total income and expense recognised directly in equity		(233,123)	2,355,132
Amounts transferred to the income statement			
Cash flow hedges Grants, donations and bequests Tax effect	Note 15 Note 5	1,289,879 - (381,661)	(669,694) 21,256 194,531
Total amounts transferred to the income statement		908,218	(453,907)
Total recognised income and expense		205,872,464	170,252,109

#### Statements of Changes in Equity for the years ended 31 December 2014 and 2013

## B) Statement of Total Changes in Equity for the year ended 31 December 2014

#### (Expressed in Euros)

#### (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)

	Registered capital	Share premium	Reserves	Treasury stock	Profit for the year	Interim dividend	Valuation adjustments	Grants, donations and bequests received	Total
Balance at 31									
December 2013	119,603,70	910,727,619	174,513,835	-	168,350,884	(68,755,491)	(669,792)	74,239	1,303,844,999
Recognised income and expense		_		<u>_</u>	205,197,369	_	669,792	5,303	205,872,464
Transactions with equity					200,107,000		000,702	0,000	200,012,101
holders or owners Net movement									
in treasury				<i>/</i>					<i></i>
stock Interim		-	-	(69,252,443)	-	-	-	-	(69,252,443)
dividend		-	-	-	-	(85,944,364)	-	-	(85,944,364)
Distribution of profit						(,,,			(,,
for the period									
Reserves		-	29,532,775	-	(29,532,775)	-	-	-	-
Dividends		-	-	-	(138,818,109)	68,755,491	-	-	(70,062,618)
Balance at 31									
December 2014	119,603,70	910,727,619	204,046,610	(69,252,443)	205,197,369	(85,944,364)	-	79,542	1,284,458,038

The accompanying notes form an integral part of the annual accounts for the year.

### Statements of Changes in Equity for the years ended 31 December 2013 and 2012

## B) Statement of Total Changes in Equity for the year ended 31 December 2013

#### (Expressed in Euros)

	Registered capital	Share premium	Reserves	Treasury stock	Profit for the year	Interim dividend	Valuation adjustments	Grants, donations and bequests received	Total
Balance at 31 December 2012	117,882,384	890,354,988	108,751,501	(3,060,444)	52,369,156	-	(2,556,138)	59,360	1,163,800,807
Recognised income and expense Transactions with equity holders or owners	-	-		-	168,350,884	-	1,886,346	14,879	170,252,109
Capital increases January 2013	1,632,820	-	(1,664,332)	-	-	-	-	-	(31,512)
Capital increase April 2013 Net movement in	88,501	20,372,631	(371,800)	-	-	-	-	-	20,089,332
treasury stock Interim dividend	-	-	11,806,429 924,627	3,060,444	-	- (68,755,491)	-	-	14,866,873 (67,830,864)
Other movement (note 12) Distribution of profit for	-	-	4,005,380	-	-	-	-	-	4,005,380
the period Reserves Dividends	-	-	51,062,030 -	-	(51,062,030) (1,307,126)	-	-	-	- (1,307,126)
Balance at 31 December 2013	119,603,705	910,727,619	174,513,835	-	168,350,884	(68,755,491)	(669,792)	74,239	1,303,844,999

#### Statements of Cash Flows for the years ended 31 December 2014 and 2013

#### (Expressed in Euros)

#### (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)

	2014	2013
Cash flows from operating activities Profit for the year before tax	175,292,168	150,957,476
· · · · · · · · · · · · · · · · · · ·		
Adjustments for:		
Amortisation and depreciation	6,565,102	5,445,344
Dividend income	(271,685,018)	(222,692,563)
Proceeds from disposals and sale of fixed assets	368,471	615
Impairment	(8,232,061)	7,314,854
Finance income	(12,883,697)	(4,939,115)
Finance costs	52,132,561	22,576,688
Exchange gains	-	(6,778,600)
Change in fair value of financial instruments	(1,148,983)	1,688,336
Other income and expense	-	(382,053)
Changes in operating assets and liabilities	<i>/-</i>	<i>(</i> )
Inventories	(2,668,360)	(126,478)
Trade and other receivables	(19,571,630)	14,838,671
Other current assets	(2,043,549)	(159,786,992)
Trade and other payables	(5,874,984)	17,712,675
Other current assets and liabilities	13,789,297	(483,351)
Other cash flows from operating activities		
Interest paid	(36,145,984)	(16,185,929)
Dividends received	271,685,018	222,692,563
Interest received	12,066,627	4,666,696
Income tax (paid) received	(3,224,532)	40,351,201
Cash flows from operating activities	168,420,446	76,870,038
Cash flows from investing activities		
Payments for investments		
Group companies and associates	(329,015,066)	(119,942,839)
Intangible assets	(5,479,590)	(3,623,494)
Property, plant and equipment	(17,929,817)	(3,288,509)
Investment property	· · ·	(1,966,137)
Other financial assets	(414,922)	-
Non-current loans to third parties	-	(14,845,067)
Proceeds from sale of investments		
Group companies and associates	2,860,085	1,000,000
Property, plant and equipment	347,820	1
Other financial assets	(372,017)	(1,319,911)
	(0	
Cash flows used in investing activities	(350,003,507)	(143,985,956)
Cash flows from financing activities		
Proceeds from and payments for equity instruments		
Issue of equity instruments		20,461,131
Acquisition of own equity instruments	(69,252,443)	(120,428,920)
Sale of own equity instruments	(09,232,443)	135,189,487
Proceeds from and payments for financial liability	-	155,169,467
instruments		
Disposal		
Loans and borrowings	(363,879,400)	(14,359,533)
Group companies and associates	683,691,323	134,818,073
Dividends and interest on other equity instruments paid	,	,,
Dividends	(156,006,982)	(69,137,990)
Cash flows from financing activities	94,552,498	86,542,248
Net increase/decrease in cash and cash equivalents	(87,030,563)	19,426,330
	(11,213,000)	,
Cash and cash equivalents at beginning of year	110,536,215	91,109,885
Cash and cash equivalents at the end of the year	23,505,652	110,536,215
ouon and baon oquivalente at the chu of the year	20,000,002	110,000,210

The accompanying notes form an integral part of the annual accounts for the year.

## Notes to the Annual Accounts

## 31 December 2014

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)

#### (1) Nature and Activities of the Company and Composition of the Group

Grifols, S.A. (hereinafter the Company) was incorporated with limited liability under Spanish law on 22 June 1987. Its registered office is in Barcelona. The Company's statutory activity consists of providing corporate and business administrative, management and control services, as well as investing in assets and property. Its principal activity involves rendering administrative, management and control services to its subsidiaries.

Its main facilities are located in Sant Cugat del Vallés (Barcelona) and Parets del Vallés (Barcelona).

Grifols, S.A.'s shares are listed on the Barcelona, Madrid, Valencia and Bilbao stock exchanges and on the electronic stock market. As of 2 June 2011 the class B non-voting shares were listed on the NASDAQ (USA) and the Automated Quotation System (SIBE/Continuous Market).

In accordance with prevailing legislation, the Company is the Parent of a Group comprising the Company and the subsidiaries listed in note 12. In accordance with generally accepted accounting principles in Spain, consolidated annual accounts must be prepared to present fairly the financial position of the Group, the results of operations and changes in its equity and cash flows. Details of investments in Group companies are provided in Appendix III.

On 20 February 2015 the Company's board of directors authorised for issue the consolidated annual accounts of Grifols, S.A. and subsidiaries for 2014 prepared in accordance with International Financial Reporting Standards as adopted by the European Union (IFRS-EU), which show consolidated profit attributable to the Parent of Euros 470,253 thousand, total assets of Euros 8,449,749 thousand and consolidated equity of Euros 2,662,888 thousand (Euros 345,551 thousand, Euros 5,841,036 thousand and Euros 2,107,204 thousand, respectively, in 2013).

#### (2) Basis of Presentation

(a) Fair presentation

The accompanying annual accounts have been prepared on the basis of the accounting records of Grifols, S.A. The annual accounts for 2014 have been prepared in accordance with prevailing legislation and the Spanish General Chart of Accounts to present fairly the equity and financial position of the Company at 31 December 2014 and results of operations, changes in equity, and cash flows for the year then ended.

The directors consider that the annual accounts for 2014, authorised for issue on 20 February 2015, will be approved with no changes by the shareholders at their annual general meeting.

(b) Comparative information

The balance sheet, income statement, statement of changes in equity, statement of cash flows and the notes thereto for 2014 include comparative figures for 2013, which formed part of the annual accounts approved by the shareholders at the annual general meeting held on 30 May 2014.

(c) Functional and presentation currency

The figures disclosed in the annual accounts are presented in Euros, the Company's functional and presentation currency, rouded off to the nearest Euro.

(d) Critical issues regarding the valuation and estimation of relevant uncertainties and judgements used when applying accounting principles

Relevant accounting estimates and judgements and other estimates and assumptions have to be made when applying the Company's accounting principles to prepare the annual accounts. A summary of the items requiring a greater degree of judgement or which are more complex, or where the assumptions and estimates made are significant to the preparation of the annual accounts, is as follows:

#### Notes to the Annual Accounts

(i) Relevant accounting estimates and assumptions

The Company tests investments in Group companies for impairment on an annual basis when the net value of the investment exceeds the carrying amount of the subsidiary and when there are indications of impairment. Fair value of the investment is measured based on estimates made by management. The Company uses cash flow discounting methods to calculate this value. Discounted cash flow calculations are based on five-year projections in the budgets approved by management. The cash flows take into consideration past experience and represent management's best estimate of future market performance. From the fifth year cash flows are extrapolated using individual growth rates. The key assumptions employed when determining fair value include growth rates and the discount rate. The estimates, including the methodology used, could have a significant impact on values and impairment.

The calculation of provisions for litigation is subject to a high degree of uncertainty. The Company recognises provisions for liabilities when an unfavourable outcome is highly probable and can be reasonably quantified. These estimates are subject to change based on new information available and on the progress of each litigation or lawsuit.

(ii) Relevant judgements used when applying accounting principles

The Company has lease contracts for its activity (see notes 7, 8 and 9). These leases are classified as operating or finance leases and require that the Company determine, based on the evaluation of the terms and conditions of these contracts, who substantially retains all the risks and rewards incidental to ownership of the assets and consequently, based on this evaluation, the contracts shall be classified as operating or finance leases

(iii) Changes in accounting estimates

Although estimates are calculated by the Company's directors based on the best information available at 31 December 2014, future events may require changes to these estimates in subsequent years. Any effect on the annual accounts of adjustments to be made in subsequent years would be recognised prospectively. Grifols management does not consider that there are any assumptions or sources of uncertainty that would have a significant risk of resulting in a material adjustment within the next financial year.

#### (3) Distribution of Profit

The distribution of profit and reserves of the Company for the year ended 31 December 2013, approved by the shareholders at their annual general meeting held on 30 May 2014, is as follows:

	Euros
Basis of allocation Profit for the year	168,350,884
Distribution Legal reserve Voluntary reserve Mandatory preferred dividend on Class B shares Dividend	344,263 29,188,513 1,307,126 137,510,982
	168,350,884

At the general meeting held on 30 May 2014, the shareholders of Grifols, S.A. approved the distribution of a mandatory preferred dividend of Euros 0.01 for every Class B share entitled to receive the dividend, with a charge to 2013 profits, for a total amount of Euros 1,307 thousand.

#### Notes to the Annual Accounts

According to the minutes to the Grifols, S.A. board of directors' meeting held on 20 October 2014, an interim dividend of Euros 0.25 for every Class A and B shares was distributed to shareholders and paid on 4 December 2014, totalling Euros 85,944 thousand and charged to 2014 profits. The amounts to be distributed did not exceed the profits reported by the Company since the end of the previous reporting period, after deducting the estimated income tax payable on these profits, as required by article 277 of the Revised Spanish Companies Act. The provisional accounting statement prepared in accordance with statutory requirements demonstrating that sufficient cash was available for distribution of the aforementioned dividend is provided in Appendix XIV.

The proposed distribution of profit for the year ended 31 December 2014 to be submitted to the shareholders for approval at their annual general meeting is as follows:

	Euros
Basis of allocation Profit for the year	205,197,369
Distribution	
Voluntary reserve	17,096,208
Mandatory preferred dividend on Class B shares	1,307,126
Dividend	186,794,035
	205,197,369

At 31 December non-distributable reserves are as follows:

	Euro	os
	2014	2013
Non-distributable reserves: Legal reserve Other	23,920,741 	23,576,478 3,020
	23,923,761	23,579,498

Profit recognised directly in equity cannot be distributed, either directly or indirectly.

#### (4) Significant Accounting Policies

- (a) Foreign currency transactions, balances and cash flows
  - (i) Foreign currency transactions, balances and cash flows

Foreign currency transactions have been translated into Euros using average exchange rates for the prior month for all foreign currency transactions during the following month. This method does not differ significantly from applying the exchange rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies have been translated into Euros at the closing rate, while non-monetary assets and liabilities measured at historical cost have been translated at the exchange rate prevailing at the transaction date.

In the statement of cash flows, cash flows from foreign currency transactions have been translated into Euros using the average exchange rates for the prior month for all flows that occur during the following month. This method does not differ significantly from applying the exchange rate at the date of the transaction.

Exchange gains and losses arising on the settlement of foreign currency transactions and the translation into Euros of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

#### Notes to the Annual Accounts

#### (b) Capitalised borrowing costs

As permitted by the second transitional provision of Royal Decree 1514/2007 approving the Spanish General Chart of Accounts, the Company opted to apply this accounting policy to work in progress at 1 January 2008 that will not be available for use, capable of operating or available for sale for more than one year. Until that date, the Company opted to recognise borrowing costs as an expense as they were incurred.

Borrowing costs related to specific and general financing that are directly attributable to the acquisition, construction or production of intangible assets, property, plant and equipment and investment property that will not be available for use, capable of operating or available for sale for more than one year are included in the cost of the asset.

To the extent that funds are borrowed specifically for the purpose of obtaining a qualifying asset, the amount of borrowing costs eligible for capitalisation is determined as the actual borrowing costs incurred. Non-commercial general borrowing costs eligible for capitalisation are calculated as the weighted average of the borrowing costs applicable to the Company's outstanding borrowings during the period, other than those specifically for the purpose of obtaining a qualifying asset and the portion financed using equity. The borrowing costs capitalised cannot exceed the borrowing costs incurred during that period.

The Company begins capitalising borrowing costs as part of the cost of a qualifying asset when it incurs expenditures for the asset, interest is accrued, and it undertakes activities that are necessary to prepare the asset for its intended use, operation or sale, and ceases capitalising borrowing costs when all or substantially all the activities necessary to prepare the qualifying asset for its intended use, operation or sale are complete, even though the necessary administrative permits may not have been obtained. Interruptions in the active development of a qualifying asset are not considered. Nonetheless, advances on account requiring adjustment do not qualify for capitalisation as borrowing costs.

Capitalised borrowing costs are recognised in the income statement under capitalised borrowing costs.

(c) Intangible assets

Intangible assets are measured at cost or cost of production. Capitalised production costs are recognised under self-constructed assets in the income statement. Intangible assets are carried at cost, less any accumulated amortisation and impairment.

Advances on account of fixed assets are initially recognised at cost. In subsequent years and provided that the period between payment and receipt of the asset exceeds one year, advances accrue interest at the supplier incremental rate.

Cost of production of intangible assets comprises the purchase price and any costs directly related to production.

Expenditure on activities that contribute to increasing the value of the Company's business as a whole, such as goodwill, trademarks and other similar items generated internally, as well as establishment costs, are recognised as expenses when incurred.

(i) Computer software

Computer software acquired and developed by the Company is recognised to the extent that costs can be clearly allocated, expensed and distributed over time to each project, and when there is evidence of technical success and economic viability. Computer software maintenance costs are charged as expenses when incurred.

#### (ii) Emission allowances

Emission allowances, which are recognised when the Company becomes entitled to such allowances, are measured at cost of acquisition. Allowances acquired free of charge, or, at a price substantially lower than fair value, are carried at fair value. Any difference between fair value and the consideration given is recognised as a non-refundable grant associated with the emission allowances and credited to equity. These grants are recognised as income and matched with the associated costs which the grants are intended to compensate, using the same criteria as for capital grants.

#### Notes to the Annual Accounts

Emission allowances are not amortised.

Provision is systematically made under current provisions for liabilities and charges for expenses related to the emission of greenhouse gases. This provision is maintained until the obligation is cancelled, through the conveyance of the corresponding rights. Provisions released or surplus provisions reversed are recognised as operating income. The provision is determined on the basis that it will be cancelled, as follows:

- Firstly, through allowances received under the emission allowances regime, which are then used to cancel actual emissions in proportion to total forecast emissions for the entire period to which they have been allocated. The expense corresponding to this part of the obligation is determined based on the carrying amount of the transferred emission allowances.
- Secondly, through the remaining emission allowances recorded. Expenditure on this part of the obligation is measured as the weighted average cost of the emission allowances.

If the emission of gases necessitates the acquisition or production of emission allowances because actual emissions exceed those which can be cancelled through the allowances assigned, or through surplus emission allowances, whether acquired or produced, provision is made for the shortfall in allowances. The expense is determined using the best estimate of the amount necessary to cover the shortfall in emission allowances.

Emission allowances acquired for resale are classified and measured using the same criteria as for inventories.

(iii) Subsequent costs

Subsequent costs incurred on intangible assets are recognised in profit and loss, unless they increase the expected future economic benefits attributable to the intangible asset.

(iv) Useful life and amortisation rates

Intangible assets with finite useful lives are amortised by allocating the depreciable amount of an asset on a systematic basis over its useful life, by applying the following criteria:

	Amortisation method	Rates	
Computer software	Straight-line	16%-33%	

The depreciable amount is the acquisition or production cost of an asset.

The Company considers the residual value of assets to be zero unless:

- There is a commitment from a third party to purchase the asset at the end of its useful life.
- There is an active market for the intangible asset, and:
- The residual value can be determined by reference to this market, and
- It is probable that this market will still exist at the end of the asset's useful life.

#### Notes to the Annual Accounts

The Company reviews the useful life and amortisation method for intangible assets at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates.

(v) Impairment losses

The Company measures and determines impairment to be recognised or reversed based on the criteria in section (f) Impairment of non-financial assets subject to amortisation or depreciation.

- (d) Property, plant and equipment
  - (i) Initial recognition

Property, plant and equipment are measured at cost of acquisition or production, using the same criteria as for determining the cost of production of intangible assets. Capitalised production costs are recognised under "Self-constructed assets" in the income statement. Property, plant and equipment are carried at cost less any accumulated depreciation and impairment.

The cost of an item of property, plant and equipment includes the estimated costs of its dismantling or removal and restoration of the site on which it is located, provided that the obligation is incurred as a consequence of having used the item.

(ii) Depreciation

Property, plant and equipment are depreciated by allocating the depreciable amount of the asset on a systematic basis over its useful life. The depreciable amount is the cost of an asset. The Company determines the depreciation charge separately for each component of an item of property, plant and equipment with a cost that is significant in relation to the total cost of the asset and with a useful life that differs from the remainder of the asset.

Property, plant and equipment are depreciated using the following criteria:

-	Depreciation method	Rates	
Buildings	Straight-line	1%-3%	
Technical installations and machinery	Straight-line	10%	
Other installations, equipment and furniture	Straight-line	4%-10%	
Other property, plant and equipment	Straight-line	7%-33%	

The Company reviews useful lives and depreciation methods at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates.

(iii) Subsequent costs

Subsequent to initial recognition of the asset, only the costs incurred which increase capacity or productivity or which lengthen the useful life of the asset are capitalised. The carrying amount of parts that are replaced is derecognised. Costs of day-to-day servicing are recognised in profit and loss as incurred.

Replacements of property, plant and equipment which meet the requirements for capitalisation are recognised as a reduction in the carrying amount of the items replaced. Where the cost of the replaced items has not been depreciated independently and it is not possible to determine their carrying amount, replacement cost is used as an indication of the cost of the items upon acquisition or construction.

#### Notes to the Annual Accounts

(iv) Impairment

The Company measures and determines impairment to be recognised or reversed based on the criteria in section (f) Impairment of non-financial assets subject to amortisation or depreciation.

#### (e) Investment property

The Company classifies property leased to its subsidiaries under this caption. All property is earmarked exclusively for own use or the use of Group companies.

Property that is being constructed or developed for future use as investment property is classified as property, plant and equipment under development until construction or development is complete. Nevertheless, redevelopment work to extend or improve property is classified as investment property.

The Company measures and recognises investment property following the policy for property, plant and equipment.

Investment property is depreciated applying the following policies:

	Depreciation method	Rates
Buildings and other installations	Straight-line	1%-10%

(f) Impairment of non-financial assets subject to amortisation or depreciation

The Company evaluates whether there are indications of possible impairment losses on non-financial assets subject to amortisation or depreciation to verify whether the carrying amount of these assets exceeds the recoverable amount. The recoverable amount is the higher of the fair value less costs to sell and the value in use.

Impairment losses are recognised in the income statement.

At the end of each reporting period the Company assesses whether there is any indication that an impairment loss recognised in prior periods may no longer exist or may have decreased. Impairment losses on goodwill are not reversible. Impairment losses on other assets are only reversed if there has been a change in the estimates used to calculate the recoverable amount of the asset.

A reversal of an impairment loss is recognised in the income statement. The increased carrying amount of an asset attributable to a reversal of an impairment loss may not exceed the carrying amount that would have been determined, net of depreciation or amortisation, had no impairment loss been recognised.

After an impairment loss or reversal of an impairment loss is recognised, the depreciation (amortisation) charge for the asset is adjusted in future periods based on its new carrying amount.

However, if the specific circumstances of the assets indicate an irreversible loss, this is recognised directly in losses on the disposal of fixed assets in the income statement.

#### (g) Leases

(i) Lessor accounting records

Leases which, on inception, transfer to third parties substantially all the risks and rewards incidental to ownership of the assets are classified as finance leases, otherwise they are classified as operating leases.

(ii) Lessee accounting records

Leases in which, upon inception, the Company assumes substantially all the risks and rewards incidental to ownership are classified as finance leases, otherwise they are classified as operating leases.

#### Notes to the Annual Accounts

- Finance leases

At the commencement of the lease term, the Company recognises finance leases as assets and liabilities at the lower of the fair value of the leased asset and the present value of the minimum lease payments. Initial direct costs are added to the asset's carrying amount. Minimum lease payments are apportioned between the finance charge and the reduction of the outstanding liability. Interest is expensed using the effective interest method.

Contingent rents are recognised as an expense when it is probable that they will be incurred.

The accounting policies applied to the assets used by the Company by virtue of finance lease contracts are the same as those set out in sections (d) and (e) (Property, plant and equipment or Investment Property).

- Operating leases

Lease payments under an operating lease, net of incentives received, are recognised as an expense on a straight-line basis over the lease term.

Contingent rents are recognised as an expense when it is probable that they will be incurred.

(iii) Sale and leaseback transactions

Asset sale and leaseback transactions that meet the conditions for classification as a finance lease are considered as financing operations and, therefore, the type of asset is not changed and no profit or loss is recognised.

- (h) Financial instruments
  - (i) Classification and separation of financial instruments

Financial instruments are classified on initial recognition as a financial asset, a financial liability or an equity instrument in accordance with the economic substance of the contractual arrangement and the definitions of a financial asset, a financial liability and an equity instrument.

The Company classifies financial instruments into different categories based on the nature of the instruments and the Company's intentions on initial recognition.

(ii) Offsetting principles

A financial asset and a financial liability are offset only when the Company currently has the legally enforceable right to offset the recognised amounts and intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

(iii) Financial assets and financial liabilities held for trading

Financial assets or financial liabilities held for trading are those which are classified as held for trading from initial recognition.

A financial asset or financial liability is classified as held for trading if it:

- Originates or is acquired or incurred principally for the purpose of selling or repurchasing it in the near term
- Forms part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking or
- Is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument.

#### Notes to the Annual Accounts

Financial assets and financial liabilities held for trading are initially recognised at fair value. Transaction costs directly attributable to the acquisition or issue are recognised as an expense when incurred.

After initial recognition, they are recognised at fair value through profit or loss. Fair value is not reduced by transaction costs incurred on sale or disposal. Accrual interest and dividends are recognised separately.

The Company does not reclassify any financial asset or financial liability into or out of this category while it is recognised in the balance sheet, except when there is a change in the classification of hedging financial instruments.

(iv) Financial assets and financial liabilities at fair value through profit or loss

Financial assets and financial liabilities at fair value through profit or loss, which comprise derivatives, are initially recognised at fair value and after initial recognition are recognised at fair value through profit or loss.

(v) Loans and receivables

Loans and receivables comprise trade and non-trade receivables with fixed or determinable payments that are not quoted in an active market other than those classified in other financial asset categories. These assets are initially recognised at fair value, including transaction costs, and are subsequently measured at amortised cost using the effective interest method.

Nevertheless, financial assets which have no established interest rate, which mature or are expected to be received in the short term, and for which the effect of discounting is immaterial, are measured at their nominal amount.

(vi) Available-for-sale financial assets

The Company classifies in this category debt securities and equity instruments which do not qualify for inclusion in the aforementioned categories.

Available-for-sale financial assets are initially recognised at fair value plus transaction costs directly attributable to the acquisition.

After initial recognition, financial assets classified in this category are measured at fair value and any gain or loss is accounted for in income and expenses recognised in equity. On disposal of the financial assets, amounts recognised in equity or the impairment loss are reclassified to profit or loss.

(vii) Investments in Group companies and associates

Group companies are those over which the Company, either directly, or indirectly through subsidiaries, exercises control as defined in article 42 of the Spanish Code of Commerce, or when the companies are controlled by one or more individuals or entities acting jointly or under the same management through agreements or statutory clauses.

Control is the power to govern the financial and operating policies of an entity or business so as to obtain benefits from its activities. In assessing control, potential voting rights held by the Company or other entities that are exercisable or convertible at the end of each reporting period are considered.

Associates are those over which the Company, directly or indirectly through subsidiaries, exercises significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over the company. The existence of potential voting rights that are currently exercisable or convertible, including potential voting rights held by the Company or a third party, are considered when assessing whether an entity has significant influence.

#### Notes to the Annual Accounts

Investments in Group companies and associates are initially recognised at cost, which is equivalent to the fair value of the consideration given, including transaction costs in the case of investments in associates, and are subsequently measured at cost net of any accumulated impairment. For investments in Group companies acquired prior to 1 January 2010 the cost of acquisition includes transaction costs.

If an investment no longer qualifies for classification under this category, it is reclassified as availablefor-sale and is measured as such from the reclassification date.

(viii) Non-monetary contributions in exchange for investments in the equity of other companies

However, in non-monetary contributions of businesses (including investments in Group companies), to Group companies, equity investments received are measured at the transaction date at the carrying amount of the assets and liabilities conveyed in the annual accounts of the contributor or at the amount representative of the percentage of interest in the equity of the contributed business, if higher. Gains or losses deferred in recognised income and expense associated with the assets and liabilities conveyed continue to be recognised in equity but are linked to the investment received.

(ix) Interest and dividends

Interest is recognised using the effective interest method.

Dividends from investments in equity instruments are recognised when the Company is entitled to receive them. If the dividends are clearly derived from profits generated prior to the acquisition date because amounts higher than the profits generated by the investment since acquisition have been distributed, the carrying amount of the investment is reduced.

Interest and dividend income are classified as revenue when they form part of the Company's ordinary activity.

#### (x) Impairment of financial assets

A financial asset or a group of financial assets is impaired and impairment losses are incurred if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset and the event or events have an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

The Company recognises impairment of loans and receivables and debt instruments when estimated future cash flows are reduced or delayed due to debtor insolvency.

For equity instruments, objective evidence of impairment exists when the carrying amount of an asset is uncollectible due to a significant or prolonged decline in its fair value.

Nevertheless, in cases in which the fair value of these instruments declines and subsequently recovers to above their quoted price, the 1.5 year period is counted from the date on which, after this recovery, the quoted price starts to drop progressively again, except when the recovery of the fair value would have been an isolated and insignificant event, in which case, the 1.5 year period is counted from the date the value first starts to decrease. This same criterion is applicable to determine whether there has been a 40% decrease in the quoted price. For this purpose, the quoted price is understood to be the initial measurement of the asset, or the weighted average price of homogeneous groups, if there had been various acquisitions.

#### Investments in Group companies

An asset is impaired when its carrying amount exceeds its recoverable amount, the latter of which is understood as the higher of the asset's value in use or fair value less costs to sell.

#### Notes to the Annual Accounts

Value in use is calculated based on the Company's share of the present value of future cash flows expected to be derived from ordinary activities and from the disposal of the asset. Unless better evidence is available, the investee's equity is taken into consideration, corrected for any unrealised gains existing at the measurement date.

In subsequent years, reversals of impairment losses in the form of increases in the recoverable amount are recognised, up to the limit of the carrying amount that would have been determined for the investment if no impairment loss had been recognised.

The recognition or reversal of an impairment loss is disclosed in the income statement unless it should be recognised in equity Impairment of an investment is limited to the amount of the investment, except when contractual, legal or constructive obligations have been assumed by the Company or payments have been made on behalf of the companies. In the latter case, provision is made.

#### Impairment of available-for-sale financial assets

When a decline in the fair value of an available-for-sale financial asset at fair value through profit or loss has been accounted for in recognised income and expense, the cumulative loss is reclassified from equity to profit or loss when there is objective evidence that the asset is impaired. The amount of the impairment loss reclassified from equity to profit or loss is calculated as the difference between the cost or amortised cost, less any impairment loss previously recognised in profit or loss, and the fair value.

Impairment losses for investments in equity instruments are not reversed through profit or loss. Increases in the fair value after the impairment loss was recognised are classified in equity.

If the fair value of debt instruments increases and the increase can be objectively related to an event occurring after the impairment loss was recognised, the increase is recognised in profit and loss up to the amount of the previously recognised impairment loss and any excess is accounted in other comprehensive income.

#### (xi) Financial liabilities

Financial liabilities, including trade and other payables, that are not classified as held for trading or as financial liabilities at fair value through profit or loss are initially recognised at fair value less any transaction costs directly attributable to the issue of the financial liability. After initial recognition, liabilities classified under this category are measured at amortised cost using the effective interest method.

Nevertheless, financial liabilities which have no established interest rate, which mature or are expected to be settled in the short term, and for which the effect of discounting is immaterial, are measured at their nominal amount.

The Company measures financial liabilities at amortised cost provided that reliable estimates of cash flows can be made based on the contractual terms.

#### Notes to the Annual Accounts

(xii) Derecognition and modifications of financial liabilities

The Company derecognises all or part of a financial liability when it either discharges the liability by paying the creditor, or is legally released from primary responsibility for the liability either by process of law or by the creditor. The exchange of debt instruments between the Company and the counterparty or substantial modifications of initially recognised liabilities are accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability, provided that the instruments have substantially different terms.

The Company considers the terms to be substantially different if the discounted present value of the cash flows under the new terms, including any fees paid net of any fees received and discounted using the original effective interest rate, is at least 10 per cent different from the discounted present value of the remaining cash flows of the original financial liability.

If the exchange is accounted for as an extinguishment of the financial liability, any costs or fees incurred are recognised as part of the gain or loss on the extinguishment. If the exchange is not accounted for as an extinguishment, any costs or fees incurred adjust the carrying amount of the liability and are amortised over the remaining term of the modified liability.

The difference between the carrying amount of a financial liability, or part of a financial liability, extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

(xiii) Reverse factoring

The Company has contracted reverse factoring facilities with various financial institutions to manage payments to suppliers. Trade payables settled under the management of financial institutions are recognised under trade and other payables in the balance sheet until they are settled, repaid or have expired.

(i) Hedge accounting

Derivative financial instruments which qualify for hedge accounting are initially measured at fair value, plus any transaction costs that are directly attributable to the acquisition, or less any transaction costs directly attributable to the issue of the financial instruments. However, transaction costs are recognised subsequently in profit or loss, when they do not form part of the effective variation in the hedge.

The Company hedges cash flows. At the inception of the hedge the Company formally designates and documents the hedging relationships and the objective and strategy for undertaking the hedges. Hedge accounting is only applicable when the hedge is expected to be highly effective at the inception of the hedge and in subsequent years to offset changes in fair value or cash flows attributable to the hedged risk, throughout the period for which the hedge was designated (prospective analysis) and the actual effectiveness, which can be reliably measured, is within a range of 80%-125% (retrospective analysis).

#### (i) Cash flow hedges

The Company recognises the portion of the gain or loss on the measurement at fair value of a hedging instrument that is determined to be an effective hedge in recognised income and expense. The ineffective portion and the specific component of the gain or loss or cash flows on the hedging instrument, excluding the measurement of the hedge effectiveness, are recognised under change in fair value of financial instruments.

The separate component of equity associated with the hedged item is adjusted to the lesser of the cumulative gain or loss on the hedging instrument from inception of the hedge and the cumulative change in fair value or present value of the expected future cash flows on the hedged item from inception of the hedge. However, if the Company expects that all or a portion of a loss recognised in equity will not be recovered in one or more future periods, it reclassifies into change in fair value of financial instruments the amount that is not expected to be recovered.

The Company prospectively discontinues hedge accounting if the foreseen circumstances affecting fair value hedges arise. In these cases, the cumulative gain or loss on the hedging instrument that has been recognised in equity is not recorded in profit or loss until the forecast transaction occurs. If the transaction is no longer expected to occur, the cumulative gain or loss that had been recognised in equity is reclassified from equity to profit or loss as change in fair value of financial instruments.

#### Notes to the Annual Accounts

(j) Own equity instruments held by the Company.

Equity instruments acquired by the Company are shown separately at cost of acquisition as a reduction in capital and reserves in the balance sheet. Any gains or losses on transactions with own equity instruments are not recognised in profit or loss.

Transaction costs related to own equity instruments, including issue costs related to a business combination, are accounted for as a deduction from reserves, net of any tax effect.

(k) Inventories

Inventories are measured using the FIFO (first in, first out) method, and mainly comprise spare parts which are stored for less than a year. When the cost of inventories exceeds replacement value, materials are written down to net realisable value.

(I) Cash and cash equivalents

Cash and cash equivalents include cash on hand and demand deposits in financial institutions. They also include other short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. An investment normally qualifies as a cash equivalent when it has a maturity of less than three months from the date of acquisition.

(m) Grants

Grants are recorded in recognised income and expense when, where applicable, they have been officially awarded and the conditions attached to them have been met or there is reasonable assurance that they will be received.

The accounting treatment of grants related to emission allowances is described in section c(ii).

(n) Defined contribution plans

The Company recognises the contributions payable to a defined contribution plan in exchange for a service when an employee has rendered service to the Company. The contributions payable are recognised as an expense for employee remuneration, and as a liability after deducting any contribution already paid. If the contribution already paid exceeds the contribution due for service before the end of the period, the Company only recognises that excess as an asset (prepaid expense) to the extent that the prepayments will lead to, for example, a reduction in future payments or a cash refund.

- (o) Provisions
  - (i) General criteria

Provisions are recognised when the Company has a present obligation (legal, contractual, constructive or tacit) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account all risks and uncertainties surrounding the amount to be recognised as a provision and, where the time value of money is material, the financial effect of discounting provided that the expenditure to be made each period can be reliably estimated. The discount rate is a pre-tax rate that reflects the time value of money and the specific risks for which future cash flows associated with the provision have not been adjusted at each reporting date.

If it is not probable that an outflow of resources will be required to settle an obligation, the provision is reversed.

#### Notes to the Annual Accounts

(ii) Provisions for taxes

Provisions for taxes are measured at the estimated amount of tax debt calculated in accordance with the aforementioned criteria. Provision is made with a charge to income tax for the tax expense for the year, to finance costs for the late payment interest, and to other income for the penalty. The effects of changes in estimates of prior years' provisions are recognised according to their nature, unless they involve the correction of an error.

(p) Revenue from the rendering of services

Revenue from the rendering of services is measured at the fair value of the consideration received or receivable.

Practically all services are rendered to Group companies.

(q) Income taxes

The income tax expense or tax income for the year comprises current tax and deferred tax.

Current tax assets or liabilities are measured at the amount expected to be paid to or recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantially enacted at the reporting date.

Current and deferred tax are recognised as income or an expense and included in profit or loss for the year, except to the extent that the tax arises from a transaction or event which is recognised, in the same or a different year, directly in equity, or from a business combination.

Government assistance provided in the form of deductions and other tax relief applicable to income tax payable is recognised as a reduction in the income tax expense in the year in which it is accrued.

The Company files consolidated tax returns with its Spanish subsidiaries: Laboratorios Grifols, S.A., Instituto Grifols, S.A., Diagnostic Grifols, S.A., Grifols Movaco, S.A., Biomat, S.A., Logister, S.A., Grifols International, S.A., Grifols Engineering, S.A., Grifols Viajes, S.A., Arrahona Optimus, S.L. and Gri-Cel, S.A.

In addition to the factors to be considered for individual taxation, set out previously, the following factors are taken into account when determining the accrued income tax expense for the companies forming the consolidated tax group:

- Temporary and permanent differences arising from the elimination of profits and losses on transactions between Group companies, derived from the process of determining consolidated taxable income.
- Deductions and credits corresponding to each company forming the consolidated tax group. For these
  purposes, deductions and credits are allocated to the company that carried out the activity or obtained
  the profit necessary to obtain the right to the deduction or tax credit.

Temporary differences arising from the elimination of profits and losses between companies in the tax group, are recognised by the company generating the profit or incurring the loss and are measured at the tax rate applicable thereto.

A reciprocal credit and debit arises between the companies that contribute tax losses to the consolidated Group and the rest of the companies that offset those losses. Where a tax loss cannot be offset by the other consolidated Group companies, these tax credits for loss carryforwards are recognised as deferred tax assets using the applicable recognition criteria, considering the tax group as a taxable entity.

The Parent of the Group records the total consolidated income tax payable with a debit to receivables from Group companies.

The amount of the debt relating to the subsidiaries is recognised with a credit to payables to Group companies.

#### Notes to the Annual Accounts

(i) Taxable temporary differences

Deferred tax liabilities derived from taxable temporary differences are recognised in all cases except where they arise from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither accounting profit nor taxable income.

(ii) Deductible temporary differences

Deferred tax assets derived from deductible temporary differences are recognised provided that it is probable that sufficient taxable income will be available against which they can be utilised. Nonetheless, assets arising from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither accounting profit nor taxable income, are not recognised.

(iii) Measurement

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the years when the asset is realised or the liability is settled, based on tax rates and tax laws that have been enacted or substantially enacted. The tax consequences that would follow from the manner in which the Company expects to recover or settle the carrying amount of its assets or liabilities are also reflected in the measurement of deferred tax assets and liabilities.

(iv) Offset and classification

The Company only offsets tax assets and liabilities if it has a legally enforceable right to offset the recognised amounts and intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

Deferred tax assets and liabilities are recognised in the balance sheet under non-current assets or liabilities, irrespective of the expected date of recovery or settlement.

(r) Classification of assets and liabilities as current and non-current

The Company classifies assets and liabilities in the balance sheet as current and non-current. Current assets and liabilities are determined as follows:

- Assets are classified as current when they are expected to be realised or are intended for sale or consumption in the Company's normal operating cycle, they are held primarily for the purpose of trading, they are expected to be realised within twelve months after the reporting date or are cash or a cash equivalent.
- Liabilities are classified as current when they are expected to be settled in the Company's normal operating cycle, they are held primarily for the purpose of trading, or they are due to be settled within twelve months after the reporting date.
- (s) Environmental issues

The Company takes measures to prevent, reduce or repair the damage caused to the environment by its activities.

Expenses derived from environmental activities are recognised as other operating expenses in the period in which they are incurred.

#### Notes to the Annual Accounts

Property, plant and equipment acquired by the Company to minimise the environmental impact of its activity and protect and improve the environment, including the reduction and elimination of future pollution from the Company's activities, are recognised as assets applying the measurement, presentation and disclosure criteria described in section (d) Property, plant and equipment.

#### (t) Transactions between Group companies

Transactions between Group companies are recognised at the fair value of the consideration given or received. The difference between this value and the amount agreed is recognised in line with the underlying economic substance of the transaction.

#### (5) Intangible Assets

- (a) Details of intangible assets and movement are shown in Appendix I.
- (b) Emission allowances

At 31 December 2014, greenhouse gas emission allowances allocated during the National Allocation Plan period, movements therein and their annual distribution are as follows:

	2014					
	Number of al	lowances	Euro	DS		
	Free of charge	Purchased	Free of charge	Purchased		
2010	31,394	11,000	398,700	135,080		
2011	(3,415)	(2,000)	(15,579)	(17,580)		
2012	3,938	(2,000)	(64,524)	(91,400)		
2013	(14,948)	(7,000)	(212,360)	(26,100)		
Total	16,969	-	106,237	-		

Impaired emission allowances amount to Euros 17 thousand at 31 December 2014 (Euros 24 thousand at 31 December 2013). During 2013 the Company adjusted grants recognised in prior years by Euros 21 thousand.

Movement in the number of allowances is as follows:

Description	Free of charge	Purchased	Total
Balances at 1 January 2013 Disposals	31,917 (14,948)	7,000 (7,000)	38,917 (21,948)
Balance at 31 December 2013	16,969	-	16,969

#### (c) Fully amortised assets

The cost of fully amortised intangible assets in use at 31 December is as follows:

	Euro	os
	2014	2013
Computer software	19,739,459	18,935,629

Fully amortised computer software in use at 31 December 2014 and 2013 mainly reflects computer licences.

## Notes to the Annual Accounts

## (6) Property, Plant and Equipment

Details of property, plant and equipment and movement are shown in Appendix II.

#### (a) Capitalised finance costs

During 2014 the Company has not capitalised finance costs on investments in progress (Euros 164 thousand in 2013) (see note 4(b)).

## (b) Fully depreciated assets

Details of the cost of fully depreciated property, plant and equipment in use at 31 December are as follows:

	Euros		
	2014	2013	
Technical installations and machinery Other installations, equipment and furniture Other property, plant and equipment	1,036,590 4,588,138 4,184,529	1,804,611 3,219,964 3,996,152	
	9,809,257	9,020,727	

#### (c) Insurance

The Company has taken out insurance policies to cover the risk of damage to its property, plant and equipment. These policies amply cover the net carrying amount of the Company's assets.

## (7) Investment Property

Details of investment property and movement during the year are as follows:

-	Euros2014			
Description	Land	Buildings and other installations	Investments in adaptation and advances	Total
Cost at 1 January 2014 Additions Disposals Transfers	4,946,480 7,563,311 - -	44,702,228 4,955,152 (1,318,040) 4,427,928	3,410,074 1,800,271 - (1,484,474)	53,058,782 14,318,734 (1,318,040) 2,943,454
Cost at 31 December 2014	12,509,791	52,767,268	3,725,871	69,002,930
Accumulated depreciation at 1 January 2014 Additions Disposals	- - -	(22,565,060) (2,056,779) 953,655	- -	(22,565,060) (2,056,779) 953,655
Accumulated depreciation at 31 December 2014	-	(23,668,184)	-	(23,668,184)
Carrying amount at 31 December 2014	12,509,791	29,099,084	3,725,871	45,334,746

#### Notes to the Annual Accounts

	Euros 2013			
Description	Land	Buildings and other installations	Investments in adaptation and advances	Total
Cost at 1 January 2013 Additions Disposals Transfers	4,946,480 - - -	43,104,144 695,283 (711) 903,512	3,599,824 1,270,854 - (1,460,604)	51,650,448 1,966,137 (711) (557,092)
Cost at 31 December 2013	4,946,480	44,702,228	3,410,074	53,058,782
Accumulated depreciation at 1 January 2013 Additions Disposals	-	(20,607,675) (1,957,480) 95	:	(20,607,675) (1,957,480) 95
Accumulated depreciation at 31 December 2013	-	(22,565,060)	-	(22,565,060)
Carrying amount at 31 December 2013	4,946,480	22,137,168	3,410,074	30,493,722

At 31 December 2014 and 2013 additions comprise the investments incurred to expand the Company's facilities.

On 10 May 2011 Grifols S.A. sold three properties located in Spain to Gripdan Invest, S.L., a wholly-owned subsidiary of Scranton Enterprises, B.V., in turn a related party of Grifols, S.A., for Euros 37.6 million. These properties related to non-core assets such as offices, warehouses and factory premises. One of the properties was sold in conjunction with its related mortgage loans, which amounted to Euros 11.5 million. The prices paid for the properties were established based on independent appraisals (see note 29).

At the same time, operating lease agreements for the aforementioned properties were entered into with Gripdan Invest, S.L., the key terms of which were as follows:

- Compulsory initial term of five years
- Initial rent established at market prices, adjusted annually for inflation (Spanish Consumer Price Index).
- Automatic five-year extensions, unless six months prior notice is given by either party.

- Upon vacating the premises, Grifols will be compensated by the lessor for any on-site assets in which it has invested, insofar as these have a residual value and are not recoverable by Grifols.

Grifols also signed a call option on the shares of Gripdan Invest, S.L., exercisable on 10 May 2016 and 10 May 2017 and for which no consideration was required. The strike price will be calculated by independent appraisers as the exercise date market value.

(a) Fully depreciated assets

The cost of fully depreciated investment property in use at 31 December is as follows:

	Euros		
	2014 2013		
Buildings Other installations	1,031,792 12,569,889	1,031,792 12,356,871	
	13,601,681	13,388,663	

## Notes to the Annual Accounts

## (b) Income and expenses from investment property

Details of income and expenses from investment property are as follows:

	Eur	Euros		
	2014	2013		
Rental income (note 25)	13,284,373	13,296,104		
Operating expenses From income-generating investments	(12,974,685)	(12,113,460)		
Net	309,688	1,182,644		

During 2014, the Company passes on costs of owned buildings and reinvoices the cost of leased buildings at market price. In 2013 the Company passed on costs of owned buildings to its subsidiaries, applying a margin of no more than 10%. It passed on the cost of general services based on the surface area occupied by each subsidiary, charging a 10% management fee.

#### (c) Insurance

The Company has taken out insurance policies to cover the risk of damage to its investment property. The coverage of these policies is considered sufficient.

#### (8) Finance Leases - Lessee

The Company has leased the following types of property, plant and equipment under finance leases:

	Euros			
	Land	Technical installations and machinery	Other property, plant and equipment	Total
<i>Initially recognised at:</i> Fair value Accumulated depreciation	435,000 (18,451)	1,815,000 (1,416,076)	4,001,505 (1,082,885)	6,251,505 (2,517,412)
Carrying amount at 31 December 2014	416,549	398,924	2,918,620	3,734,093
Initially recognised at: Present value of minimum lease payments Accumulated depreciation	435,000 (9,595)	1,815,000 (1,293,330)	2,446,445 (592,505)	4,696,445 (1,895,430)
Carrying amount at 31 December 2013	425,405	521,670	1,853,940	2,801,015

Future minimum lease payments are reconciled with their present value as follows:

	Euros		
	2014	2013	
Future minimum payments Unaccrued finance costs	3,639,816 (515,774)	2,747,742 (347,665)	
Present value	3,124,042	2,400,087	

#### Notes to the Annual Accounts

Details of minimum payments and the present value of finance lease liabilities, by maturity date, are as follows:

	Euros			
	20	14	20	13
	Minimum		Minimum	
	payments	Present value	payments	Present value
Less than one year	1,031,745	949,505	1,010,520	946,209
One to five years	2,608,071	2,174,537	1,737,222	1,453,878
	3,639,816	3,124,042	2,747,742	2,400,087
Less current portion	(1,031,745)	(949,505)	(1,010,520)	(946,209)
Total non-current	2,608,071	2,174,537	1,737,222	1,453,878

## (9) Operating Leases - Lessee

The Company has contracted offices and land under operating leases from related parties and Group companies.

The most significant lease contracts are as follows:

#### Offices located in Sant Cugat del Vallès (Barcelona), leased from a Group company

The Company has leased the offices in which it operates from one of its subsidiaries since September 2009. The lease contract is valid for one year and is automatically renewed on an annual basis.

## Land located in Parets del Vallés (Barcelona), leased from a third party

This contract is valid for 30 years from 1996 and is automatically renewable for five-year periods. One year's notice must be given if either party wishes to cancel the contract.

#### Offices located in Parets del Vallés (Barcelona), leased from a third party

This contract is valid for ten years from 2005 and can be renewed for between one and twenty years at the lessee's discretion, which the lessor is obliged to accept, and can be cancelled at any moment in time with four months' notice.

#### Offices located in Parets del Vallés and Barcelona, leased from a related party.

This contract is valid for five years from 2011 and compliance is compulsory for both parties. Once the initial term has elapsed, the contract will be automatically renewed for successive periods of five years unless the parties notify of their intention not to renew it, within six months of the end of the initial term (note 7).

Operating lease payments have been recognised as an expense for the year as follows:

	Euros	
	2014	2013
Minimum lease payments	8,813,088	8,993,778

Future minimum payments under non-cancellable operating leases are as follows:

#### Notes to the Annual Accounts

	Euros	
	2014	2013
Less than one year	4,153,297	4,654,280
One to five years	1,668,750	5,346,483
Over five years	327,155	582,895
	6,149,202	10,583,658

The Company uses part of these premises for its own use and sub-leases the rest to its Spanish subsidiaries (see note 7 (b)).

#### (10) Operating Leases - Lessor

As described in note 7(b) and note 25, the Company leases and sub-leases premises and installations that it owns and leases from third parties to its Spanish subsidiaries.

Contracts signed with its subsidiaries are renewed automatically on an annual basis and can be cancelled at any time with three months' prior notice. The minimum non-cancellable amount receivable totals Euros 3,321 thousand at 31 December 2014 (Euros 3,324 thousand in 2013).

#### (11) Risk Management Policy

(a) Financial risk factors

The Company's activities are exposed to various financial risks: market risk (including currency risk, interest rate risk in fair value and price risk), credit risk, liquidity risk and interest rate risk in cash flows. The Company's global risk management programme focuses on uncertainty in the financial markets and aims to minimise potential adverse effects on the Company's profits. The Company used derivatives to mitigate certain risks.

The Company's risk management policies are established in order to identify and analyse the risks to which the Company is exposed, establish suitable risk limits and controls, and control risks and compliance with limits. Risk management procedures and policies are regularly reviewed to ensure they take into account changes in market conditions and in the Company's activities. The Company's management procedures and rules are designed to create a strict and constructive control environment in which all employees understand their duties and obligations.

The Group's Audit Committee supervises how management controls compliance with the Group's risk management procedures and policies and reviews whether the risk management policy is suitable considering the risks to which the Group is exposed. This committee is assisted by Internal Audit which acts as supervisor. Internal Audit performs regular and ad hoc reviews of the risk management controls and procedures and reports its findings to the Audit Committee.

#### (i) Market risk

The Company is not exposed to market risks associated with non-financial assets.

(ii) Currency risk

The Company operates internationally and is therefore exposed to currency risk when operating with foreign currencies, especially with regard to the US Dollar. Currency risk is associated with recognised assets and liabilities, and net investments in foreign operations.

The Company holds several investments in foreign operations, the net assets of which are exposed to currency risk. Currency risk affecting net assets of the Company's foreign operations in US Dollars is mitigated primarily through borrowings in the corresponding foreign currency.

Details of financial monetary assets and liabilities in foreign currencies and transactions in foreign currencies are provided in notes (14) and (21).

#### Notes to the Annual Accounts

At 31 December 2014 had the US Dollar weakened by 10% against the Euro, with the other variables remaining constant, post-tax profit would have been Euros 1,125 thousand higher, mainly as a result of translating payables to Group companies.

(iii) Credit risk

The Company's financial assets mainly comprise the trade receivables from and loans to Group companies.

Derivative and cash transactions are only carried out using financial instruments with a high credit rating.

The Company considers that its financial assets are not significantly exposed to credit risk.

(iv) Liquidity risk

The Company applies a prudent policy to cover its liquidity risks based on having sufficient cash, as well as sufficient financing through credit facilities, to settle market positions.

Details of financial liabilities by contractual maturity date are provided in note (21).

(v) Cash flow and fair value interest rate risks

Interest rate risk arises on loans extended to Group companies and current and non-current borrowings. Borrowings and loans extended at variable interest rates expose the Company to cash flow interest rate risks. The Company's policy involves contracting borrowings and extending loans to Group companies at variable interest rates.

The Company manages cash flow interest rate risks through interest rate swaps. The variable to fixed interest rate swaps convert variable interest rates on borrowings to fixed interest rates. The Company generally obtains non-current borrowings with variable interest rates (see note 21) and on occasions swaps these for fixed interest rates that are normally lower than if the financing had been obtained directly with fixed interest rates. Through variable to fixed interest rate swaps the Company undertakes to exchange the difference between fixed interest and variable interest with other parties on a monthly basis. The difference is calculated based on the contracted notional principal amount. At 31 December 2013 the Company had two interest-rate swaps for loans, one of which was from variable to fixed, for which the Company applied hedge accounting (see note 15) and the other swap had a variable interest rate. The notional amount of these swaps was Euros 100,000 thousand each (see note 15). As at 31 December 2014, these swaps have been cancelled.

At 31 December 2014, had interest rates been 10 basis points higher/lower, with the other variables remaining constant, post-tax profit would have been Euros 300 thousand lower/higher, mainly because of higher borrowing costs on variable interest debt.

#### **Notes to the Annual Accounts**

#### (12) Investments in Equity Instruments of Group Companies and Associates

Details of investments in equity instruments of Group companies are as follows:

	Euros	
	2014	2013
	Non-current	Non-current
Group companies Investments	1,610,563,463	1,305,061,532
Impairment	(11,520,575)	(14,380,720)
	1,599,042,888	1,290,680,812
Associates Investments	42,788,922	20,635,872
	42,788,922	20,635,872
Total	1,641,831,810	1,311,316,684

During 2014 the following changes to Company investments in equity instruments have taken place:

- The Company subscribed to the share capital increase issued by Laboratorios Grifols S.A. for an amount of Euros 7,000 thousand.
- The Company subscribed to the share capital increase issued by Movaco S.A. for an amount of Euros 1,500 thousand.
- The Company subscribed to the share capital increase issued by Grifols Brasil Ltda. for an amount of Euros 3,944 thousand. In 2013 the Company subscribed to the share capital increase issued by this company for an amount of Euros 3,571 thousand.
- The Company subscribed to the share capital increase issued by Grifols Colombia Ltda for an amount of Euros 814 thousand.
- The Company subscribed to the share capital increase issued by Grifols Pharmaceutical Consulting (Shanghai) Co., Ltd. for an amount of Euros 600 thousand (incorporated in 2013 with an investment of Euros 400 thousand).
- In 2013 the Company incorporated Grifols Diagnostics Solutions Inc (formerly G-C Diagnostics Corp.). On 9 January 2014 the Grifols Group acquired the transfusional medicine and immunology diagnostic unit of the Swiss company Novartis International AG for approximately USD 1,653 million (Euros 1,215 million). The transaction was carried out through the newly-incorporated subsidiary, Grifols Diagnostics Solutions (formerly G-C Diagnostics Corp.) (USA), which is wholly-owned by the Company. At 31 December 2014 the amount of the investment is Euros 293,794 thousand.
- The Company incorporated Grifols Japan KK. Its investment in this company amounts to Euros 709 thousand.
- The Company incorporated Grifols India Healthcare Private. Its investment in this company amounts to Euros 1,300 thousand.
- The Company has sold ownership of Grifols International, SA to another Group company by Euros 2,860 thousand. The investment in the transferred entity was fully impaired, generating income of Euros 2,860 thousand.

#### Notes to the Annual Accounts

- The Company acquired 50% of Kiro Robotics, S.L. for Euros 22,153 thousand.

During 2013 the following changes to Company investments in equity instruments took place:

- The Company subscribed to the share capital increase issued by Grifols Nordic AB for an amount of Euros 1,783 thousand.
- The Company acquired shares representing 60% of the economic and voting rights (56.1% after Ekarpen capital increase described below) of Progenika Biopharma, S.A. for an amount of Euros 37,010 thousand. The acquisition was paid through the following:
  - 50% of the purchase price was paid with 884,997 Class B non-voting Grifols shares, with a fair value of Euros 20.91 per share. The Group guaranteed the vendor shareholders a resale option on the Class B shares at the same price during the 5 days subsequent to the sale. Vendor shareholders holding 879,913 shares executed this option and the cash paid amounted to Euros 18,399 thousand, being considered as cash for investment activities in the statement of cash flows.
  - The remaining 50% of the price had been paid in cash (Euros 18,505 thousand).

The Class B non-voting Grifols shares, used as consideration for the acquisition of the Progenika shares, were lent by a related party under a share loan agreement signed on 12 February 2013 (note 25). On 16 April 2013 share capital was increased in the nominal amount of Euros 88,499.70 by issuing and placing in circulation 884,997 new Class B non-voting shares (note 18). The capital increase enabled the Company to return the non-voting shares to the lender, which were lent pursuant to the provisions of the share loan agreement.

In addition, the Company and the vendor shareholders granted a reciprocal put and call option for the 35% (32.9% after Ekarpen capital increase explained below) of shares still held by these shareholders, which may be exercised in a period of three years. The sale/purchase price of the shares affected by the option had been set at Euros 21,701 thousand, plus simple annual interest of 5% and this amount had been treated as a financial liability. Grifols, Progenika and the investment vehicle EKARPEN SPE, S.A. (hereinafter Ekarpen), owned by the Basque Government, Kutxabank, Caja Laboral-Euskadiko Kutxa, Lagun Aro and the Provincial Governments of the Basque Country, agreed that the share capital of Ekarpen be increased by a total of Euros 5,000 thousand, whereby Ekarpen received new shares representing approximately 6.5% of the share capital of Progenika. These shares are subject to a put and call option which may be exercised at the end of a 5-year period for a purchase price of Euros 300 thousand for each of the five-year periods. Additionally, an amount of Euros 1,643 thousand consisting of participating loans extended to Progenika Biopharma, S.A. had been treated as an investment.

The Company acquired 99.98 % of Logister S.A. from another Group company. Its investment in this company amounted to Euros 105 thousand.

The Company incorporated Grifols Worldwide Operations Limited. Its investment in this company amounted to Euros 56,505 thousand, of which Euros 4,005 thousand consisted of the contribution from the subsidiary Squadron Reinsurance, Ltd to Grifols Worldwide Operations, Ltd. The investment in Squadron Reinsurance Ltd had a carrying amount of Euros 1,000 thousand.

The Company acquired a 35% interest in Aradigm Corporation. Its investment in this company amounted to Euros 20,636 thousand.

The Company incorporated Grifols Switzerland AG. Its investment in this company amounted to Euros 81 thousand.

After analysing the likelihood of recovering its investment in Grifols Nordic the Company recognised impairment of Euros 3,027 thousand on this investment.

The Company subscribed to the share capital increase issued by Gri-Cei, S.A. for an amount of Euros 2,321 thousand.

#### Notes to the Annual Accounts

At 31 December 2011 the Company recognised impairment of Euros 6,583 thousand for the investment in Arrahona Optimus, S.L based on the analysis of its recoverability. On 31 December 2013 the Company reversed Euros 163 thousand of the provision.

(a) Investments in Group companies

Details of investments in Group companies are provided in Appendix III.

Subsidiaries' activities comprise the following:

- Industrial activity: consisting of the manufacture, preparation and sale of therapeutic products and other pharmaceutical specialities, particularly haemoderivatives and parenteral solutions, reagents, chemical products for use in laboratories and healthcare centres, and medical-surgical materials, equipment and instruments; the collection and analysis of products of biological origin, and the procurement of human plasma.

- Commercial activity: consisting primarily of the marketing of products manufactured by the industrial Group companies.

- Service activity: comprising the management of business trips for Group companies, the preparation and implementation of engineering projects for both the Group and third parties, and the rendering of centralised services such as accounting, human resources, marketing, etc. This activity also includes the reinsurance of the Group's insurance policies.

- Research activity: includes research activities in different fields such as biotechnology, nanotechnology and genetic and cellular therapy tools, as well as the development of new products and applications for existing products.

The percentage ownerships included in Appendix III agree with the voting rights the Company has in its subsidiaries, except for Grifols Thailand, Ltd. (48% ownership) and Grifols Malaysia Sdn Bhd (30% ownership), in which the Company has majority voting rights through the type of shares it holds in Grifols Thailand, Ltd, and through a contract entered into with the other shareholder and the pledging of this shareholder's shares in Grifols Malaysia.

#### (i) Foreign currency

The functional currencies of foreign operations are the currencies of the countries in which they are domiciled, except Grifols Worldwide Operations Limited with functional currency US Dollars.

(b) Other information

Subsidiaries have been audited/reviewed by companies associated with KPMG International in the countries in which they have their registered office, except for Grifols Chile, S.A. (audited by Surlatina Auditores, Ltda., a member of Grant Thornton) and Grifols Argentina, S.A. (audited by Alexia Consulting Group, S.R.L.).

Grifols France, S.A.R.L., Grifols Malaysia SDN BHD, Grifols Viajes, S.A., Logister, S.A., Arrahona Optimus, S.L. and GriCel, S.A. have not been audited.

#### (13) Financial Assets by Category

(a) Classification of financial assets by category

The classification of financial assets by category and class and a comparison of the fair value and the carrying amount are provided in Appendix IV.

#### Notes to the Annual Accounts

#### (i) Net losses and gains by category of financial asset

Net losses and gains by category of financial asset are as follows:

	Euros	
2014	Loans and receivables	Total
Finance income at amortised cost, Group companies Finance income at amortised cost	13,309,791 45,870	13,309,791 45,870
Net gains in profit or loss	13,355,661	13,355,661
Total	13,355,661	13,355,661

	Euros				
2013	Held-for-trading assets	Loans and receivables	Available-for-sale financial assets	Total	
Finance income at amortised cost, Group companies	<u>-</u>	4,387,719	_	4,387,719	
Finance income at amortised cost	-	387,701	-	387,701	
Change in fair value	(7,668)	-	-	(7,668)	
Losses on disposal	-	-	(476,483)	(476,483)	
Net gains/(losses) in profit or loss	(7,668)	4,775,420	(476,483)	4,291,269	
Total	(7,668)	4,775,420	(476,483)	4,291,269	

## (14) Investments and Trade Receivables

#### (a) Investments in Group companies

Details of investments in Group companies and related parties are as follows:

	Euros				
	2014	l.	2013	3	
	Non-current	Current	Non-current	Current	
Group					
Loans	16,410,455	201,659,132	18,158,520	545,660,430	
Receivables, tax effect (note					
23)	-	23,175,818	-	2,472,096	
Interest	-	1,921,323	-	632,289	
Impairment	-	(4,645,690)	-	(9,976,880)	
Total	16,410,455	222,110,583	18,158,520	538,787,935	

#### Notes to the Annual Accounts

#### (b) Investments

Details of investments are as follows:

	Euros			
	201	4	201	3
	Non-current	Current	Non-current	Current
Unrelated parties Assets available for sale Deposits and guarantees Other Impairment	- 839,307 3,294,621 -	- 8,802 - -	245,298 811,793 2,900,442 (245,298)	- 15,573 - -
Total	4,133,928	8,802	3,712,235	15,573

The Company's interest of less than 2% in Cardio BioSciences (Belgium), acquired in 2008, was fully impaired at 31 December 2012. In 2013 this interest was sold, incurring a loss of Euros 476 thousand in respect of the cost of acquisition and the provision was reversed.

At 31 December 2014 and 2013 the balance of deposits and guarantees consists of the new lease with Gripdan Invest, S.L. a company wholly owned by Scranton Enterprise B.V, which is a related party to Grifols S.A. (see notes 7 and 25).

At the end of December 2011 the Company contracted a call option on the shares of Scranton Investments, B.V., a shareholder of Scranton Enterprises USA, Inc. This option, which had a cost of USD 4,000 thousand ,Euros 3,295 thousand at 31 December 2014; (Euros 2,900 thousand at 31 December 2013), can be exercised on the date the Food and Drug Administration (FDA) grants the licence for a plant located in Clayton, USA which belongs to that company and is leased to the Group company Grifols Therapeutics, Inc. The option may also be exercised at five and ten years from the licence date, and on the expiry date of the lease contract. The purchase price will vary depending on the market value determined on the date the option is exercised.

(c) Trade and other receivables

Details of trade and other receivables are as follows:

	Euros		
	2014	2013	
	Current	Current	
Group			
Trade receivables (note 25) Associates	32,506,427	11,918,832	
Trade receivables (note 25) Unrelated parties	11,215	6,976	
Trade receivables	365,051	824,198	
Other receivables	68,284	631,923	
Personnel Taxation authorities, income	11,410	8,827	
tax (note 23) Public entities, other (note	47,190,583	22,340,496	
23)	5,351,265	7,738,524	
Total	85,504,235	43,469,776	

#### Notes to the Annual Accounts

At 31 December 2014 and 2013 public entities, other predominantly comprise recoverable value added tax and income tax. The Company files consolidated VAT and income tax returns.

#### (d) Amounts denominated in foreign currencies

Details of monetary financial assets denominated in foreign currencies are as follows:

	Euros			
		Swiss	Pound	
2014	US Dollar	Franc	Sterling	Total
Non-current investments in Group companies and associates				
Loans to companies	3,247,918	-	-	3,247,918
Non-current investments	0.004.004	0.004.044		
Loans to related companies	3,294,621	2,661,344	-	5,955,965
Total non-current financial assets	6,542,539	2,661,344	_	9,203,883
	0,012,000	2,001,011		0,200,000
Trade and other receivables Trade receivables – current	441	-	_	441
Trade receivables from Group companies and				
associates – current	607,616	3,682,123	19,461	4,309,200
Other receivables	139,260	-	-	139,260
Current financial investments in Group companies and associates				
Loans to companies	686,897	182,856	-	869,753
Total current financial assets	1,434,214	3,864,979	19,461	5,318,654
Total financial assets	7,976,753	6,526,323	19,461	14,522,537

		Euros	
2013	USD Dollar	Swiss Franc	Total
Non-current investments in Group companies and associates Loans to companies	2,859,327	3,258,390	6,117,717
Non-current investments Loans to related companies	2,900,442		2,900,442
Total non-current financial assets	5,759,769	3,258,390	9,018,159
Trade and other receivables Trade receivables – current	173,023	-	173,023
Current investments Loans to companies	72,539,190	950,590	73,489,780
Total current financial assets	72,712,213	950,590	73,662,803
Total financial assets	78,471,982	4,208,980	82,680,962

#### Notes to the Annual Accounts

Details of exchange differences recognised in profit or loss on financial instruments, distinguishing between settled and outstanding transactions, are as follows:

	Euros			
	201	14	<b>20</b> 1	3
	Settled	Outstanding	Settled	Outstanding
Investments in Group companies Loans to Group companies	(2,272,887)	279,382	180,699	2,773,449
Total non-current financial assets	(2,272,887)	279,382	180,699	2,773,449
Trade and other receivables Trade receivables – current	30,458	11,114	(3,493)	(5,547)
Trade receivables from Group companies – current <i>Current investments</i> Loans to Group companies	- (31,877)	(2,578)	- (254)	(986)
Total current financial assets	(1,419)	8,536	(3,747)	(6,533)
Total financial assets	(2,274,306)	287,918	176,952	2,766,916

#### (15) Derivative Financial Instruments

At 31 December 2014 the Company has not recognised any derivative financial instruments. Details of derivative financial instruments are at 31 December 2013 are as follows:

	_	Euros
		Fair values
		Liabilities
2013	Notional amount	Non-current
Derivatives held for trading and at fair value through profit or loss Interest rate derivatives		
Embedded floor in senior debt (note 21 (c))	196,000,000	(3,539,005)
Total derivatives at fair value through profit or loss (note 21)	196,000,000	(3,539,005)
Embedded derivatives Foreign currency	100,000,000	(4,024,954)
Total embedded derivatives	100,000,000	(4,024,954)
Total derivatives at fair value through profit or loss	296,000,000	(7,563,959)

#### Notes to the Annual Accounts

On 17 March 2014 the Grifols Group refinanced its secured senior debt, which is held by the Group company Grifols Worldwide Operations Limited. Consequently, at 31 December 2014 the Company does not have any loans or embedded derivatives in its books. At 31 December 2013 the floor included in the tranche B senior debt constituted an embedded derivative measured at fair value and recognised separately from loans.

#### (a) Interest rate swaps

The Company has no interest rate swaps at 31 December 2014. At 31 December 2013 the Company used interest rate swaps to manage its exposure to interest rate fluctuations for some of its bank loans.

At 31 December 2013 the Company held two swap contracts, each for a notional amount of Euros 100 million and expiring on 31 March 2016. The variable to fixed interest swap hedged the Company against a possible rise in the variable interest rate to which part of the Group's financing is pegged. The swap met all the prerequisites to qualify for hedge accounting: throughout the term of this contract the notional amount will be equal to or less than the balance of the loans; the term of the contract does not exceed the maturity date of the loans; and the settlement dates and terms of the derivative contract are the same as those for repayment of the loans.

#### (b) Cash flow hedges

The total amount of cash flow hedges recognised in equity is as follows:

Interest rate swaps

	Euros Income/(Expenses)		
	2014	2013	
Finance income	38,984	3,364,464	

The total amount of cash flow hedges transferred from recognised income and expense to profit or loss and details of the income statement headings under which these items have been recognised are as follows:

	Euros Gains/(Losses)		
	2014	2013	
Finance income/(costs)	917,862	(669,694)	

The total amount of the ineffective portion of cash flow hedges recognised as changes in fair value of financial instruments in the income statement is as follows:

Euros		
2014	2013	
13,676	1,015,470	

#### (16) Inventories

Inventories are mainly spares used to maintain the Company's buildings and facilities. At 31 December 2014 the figure includes spare parts acquired from the Group company Instituto Grifols, S.A.

#### Notes to the Annual Accounts

#### (17) Prepayments

At 31 December 2014 prepayments include advanced payments for insurance premiums and professional service fees.

#### (18) Equity

Details of equity and movement during the year are shown in the statement of changes in equity.

(a) Capital

At 31 December 2014 the share capital of Grifols S.A. amounts to Euros 119,603,705 and is represented by:

<u>Class A shares:</u> 213,064,899 ordinary shares of Euros 0.50 par value each, subscribed and fully paid and of the same class and series.

<u>Class B Shares:</u> 130,712,555 non-voting preference shares of Euros 0.10 par value each, of the same class and series, and with the preferential rights set forth in the Company's by-laws.

Since 23 July 2012 the ADSs (American Depositary Shares) representing Grifols, S.A.'s Class B non-voting shares have had an exchange ratio of 1:1 in relation to Class B shares; i.e. 1 ADS represents 1 Class B share. The ratio was previously 2 ADSs to each Class B share.

On 4 December 2012, the shareholders of Grifols approved a share capital increase through the issue of 16,328,212 new Class B non-voting shares, with a charge to voluntary reserves. This issue was executed in a public deed on 4 January 2013 and the shares were admitted for trading on the four Spanish stock exchanges and the Spanish Automated Quotation System on 14 January 2013.

On 16 April 2013 Grifols increased its share capital by issuing 884,997 Class B non-voting shares of Euros 0.10 par value each, with a share premium of Euros 23.02 per share. Therefore, the total amount of the share capital increase had been Euros 20,461,131, of which Euros 88,499.70 corresponded to the par value and Euros 20,372,630.94 to share premium. The board of directors agreed to suppress the pre-emptive subscription rights in connection with this share capital increase.

The aforementioned share capital increase had enabled Grifols to return to the lender the non-voting shares to comply with the commitment with the vendors of Progenika shares pursuant to the provisions of the share loan agreement signed in February 2013.

The main characteristics of the Class B shares are as follows:

• Each Class B share entitles its holder to receive a minimum annual preferred dividend out of the distributable profits at the end of each year equal to Euros 0.01 per Class B share provided that the aggregate preferred dividend does not exceed the distributable profits for that year and a distribution of dividends has been approved by the Company's shareholders. This preferred dividend is not cumulative if sufficient distributable profits are not obtained in the period.

•Each Class B share holder is entitled to receive, in addition to the above-mentioned preferred dividend, the same dividends and other distributions as for one Grifols ordinary share.

• Each Class B share entitles the holder to its redemption under certain circumstances, if a takeover bid for all or part of the shares in the Company has been made, except if holders of Class B shares have been entitled to participate in the bid on the same terms as holders of Class A shares. The redemption terms and conditions reflected in the Company's by-laws limit the amount that may be redeemed, requiring that sufficient distributable reserves be available, and limit the percentage of shares to be redeemed in line with the ordinary shares to which the bid is addressed.

• In the event the Company were to be wound up and liquidated, each Class B share entitles the holder to receive, before any amounts are paid to holders of ordinary shares, an amount equal to the sum of (i) the par value of the Class B share, and (ii) the share premium paid for the Class B share when it was subscribed. In addition to the Class B liquidation preference amount, each holder is entitled to receive the same liquidation amount that is paid for each ordinary share. These shares are freely transferable.

The Company's knowledge of its shareholders is based on information provided voluntarily or in compliance with applicable legislation. According to the information available to the Company, there are no interests higher than 10% with voting rights at 31 December 2014 and 2013.

#### Notes to the Annual Accounts

(b) Share premium

This reserve is freely distributable.

(c) Reserves

Details of reserves and movement during the year are shown in Appendix V.

(i) Legal reserve

The legal reserve has been appropriated in compliance with article 274 of the Spanish Companies Act, which requires that companies transfer 10% of profits for the year to a legal reserve until this reserve reaches an amount equal to 20% of share capital.

The legal reserve is not distributable to shareholders and if it is used to offset losses, in the event that no other reserves are available, the reserve must be replenished with future profits.

(ii) Treasury stock and reserve for Company shares

At the ordinary general meeting held on 24 January 2011 the shareholders of the Company agreed to authorise the acquisition of a maximum of treasury stock equivalent to 10% of the Company's share capital at a minimum price equal to the par value of shares and a maximum equal to the price quoted on the stock exchange on the date of acquisition or, where applicable, the price authorised by the Spanish National Securities Market Commission.

This acquisition has been authorised for a period of five years from the date this decision was taken. Shares acquired may be handed over to the Group's employees or directors either directly or as a result of them exercising share options they may hold.

The Company held Class A and B treasury stock equivalent to 0.82% of its capital at 31 December 2014. The Company does not hold any Class A treasury stock at 31 December 2013.

Details of Class A and B treasury stock at 31 December 2014 and 2013 are provided in Appendix XV.

On 11 March 2013 Grifols S.A. purchased 4,402,986 of its American Depositary Shares ("ADSs") from various funds managed by Cerberus Capital Management, L.P. and/or its affiliated advisory entities for a total of Euros 88.9 million (US Dollars 118.9 million, or USD 27 per ADS). Grifols originally issued the ADSs to Cerberus in June 2011, in connection with the acquisition of Talecris Biotherapeutics Corp. Cerberus was the majority shareholder of Talecris. In November 2013, the Company sold all the ADSs forming part of its treasury stock. The sale generated a profit of Euros 11.2 million, which has been recognised in reserves.

Cash acquisitions included the purchase of the Class B shares from the vendor shareholders of Progenika for which Grifols exercised the cash option for an amount of Euros 18,399 thousand. This amount had been considered as cash used in investing activities in the statement of cash flows. Cash acquisitions also included purchases of Class B shares issued on 16 April 2013 and subscribed by a financial institution (see section (a) of this note).

Non-cash acquisitions and disposals of Class B shares included a share loan transaction entered into with a related party (see note 25). Subsequent disposals included Class B shares exchanged in the acquisition of Progenika Biopharma, S.A. (see note 12). Cash obtained through disposals of Class A and B shares amounted to Euros 15,286 thousand and Euros 119,903 thousand, respectively.

(iii) Differences on redenomination of capital to Euros

This reserve is not distributable.

(iv) Voluntary reserves

These reserves are freely distributable.

#### Notes to the Annual Accounts

#### (19) Other Provisions, Other Guarantees with Third Parties and Other Contingent Liabilities

Movement in other provisions is as follows:

	Euros		
	Provisions for		
	taxes	Total	
At 1 January 2014	185,517	185,517	
Charges	500,000	500,000	
At 31 December 2014	685,517	685,517	

#### (a) Contingencies

Contingent liabilities for bank and other guarantees are disclosed in note 21. The Company does not expect any significant liabilities to arise from these guarantees.

In the event of a takeover, the Company has agreements with 29 employees/directors whereby they can unilaterally rescind their employment contracts with the Company and are entitled to termination benefits ranging from two to five years' salary.

The Company also has a contract with a member of senior management who will receive a termination benefit ranging from one to two years' salary, depending on the circumstances.

#### (20) Financial Liabilities by Category

(a) Classification of financial liabilities by category

The classification of financial liabilities by category and class and a comparison of the fair value with the carrying amount are provided in Appendix VI.

(i) Net losses and gains by financial liability category

Net losses and gains by financial liability category are as follows:

.

	Euros			
2014	Held-for- trading liabilities	Debts and payables	Hedging derivatives	Total
Finance costs at amortised cost, third parties		(26,683,805)		(26,683,805)
Finance costs at amortised cost, Group companies Change in fair value of derivative	-	(27,445,636)		(27,445,636)
financial instruments	3,539,005	-	(1,289,879)	2,249,126
Net gains/(losses) in profit or loss	3,539,005	(54,129,441)	(1,289,879)	(51,880,315)
Change in fair value of derivative financial instruments			956,846	956,846
Net gains/(losses) in equity	-	-	956,846	956,846
Total	3,539,005	(54,129,441)	(333,033)	(50,923,469)

# Notes to the Annual Accounts

	Euros			
2013	Held-for- trading liabilities	Debts and payables	Hedging derivatives	Total
Finance costs at amortised cost, third parties Finance costs at amortised cost,	-	(23,608,880)	-	(23,608,880)
Group companies Change in fair value of derivative	-	(749,465)	-	(749,465)
financial instruments	2,426,377	-	(2,700,634)	(274,257)
Net gains/(losses) in profit or loss	2,426,377	(24,358,345)	(2,700,634)	(24,632,602)
Change in fair value of derivative financial instruments	-	-	2,694,780	2,694,780
Net gains in equity	-	-	2,694,780	2,694,780
Total	2,426,377	(24,358,345)	(5,854)	(21,937,822)

# (21) Payables and Trade Payables

#### (a) Group companies and associates

Details of payables to Group companies and associates are as follows:

		Euros		
-	2014		201	3
	Non-current	Current	Non-current	Current
Group				
Payables	29,610,743	199,622,090	-	132,051,579
Loans received	378,136,055	-	86,201,597	46,053,256
Payables, tax				
effect (note		26,849,084		
23)	-		-	38,103,481
Interest	1,789,612	850,269	-	304,764
Associates				
		3,059,403		
Loans received	-		-	2,682,917
Total	409,536,410	230,380,846	86,201,597	219,195,997

Details of payables to Group companies do not include trade payables to Group companies, details of which are provided in section d) of this note.

#### Notes to the Annual Accounts

(b) Debts

Details of debts are as follows:

	Euros				
	2014	ŀ	2013		
	Non-current	Current	Non-current	Current	
Unrelated parties					
Loans and borrowings	14,211,247	4,759,661	332,229,183	37,628,778	
Interest	-	50,679	-	1,368	
Finance lease payables (note					
8)	2,174,537	949,505	1,453,878	946,209	
Derivative financial					
instruments (note 15)	-	-	7,563,959	-	
Debts	30,263,666	996,088	28,994,025	840,752	
Guarantees and deposits					
received	-	5,765	-	5,765	
Total	46,649,450	6,761,698	370,241,045	39,422,872	

At 31 December 2014 non-current payables include Euros 28,724 thousand (Euros 27,624 thousand at 31 December 2013), reflecting a put and call option granted by the Company and the shareholders of Progenika.

- (c) Other information on payables
  - (i) Main characteristics of payables

The terms and conditions of loans and payables are provided in Appendix VIII.

On 17 March 2014 the Grifols Group refinanced its secured senior debt, being assumed by the Group company Grifols Worldwide Operations Limited. At 31 December 2014 the Company does not have any loans or embedded derivatives in its books.

The total debt refinanced amounts to US Dollars 5,500 million (Euros 4,075 million) and represents Grifols' entire debt, including the US Dollars 1,500 million bridge loan obtained for the acquisition of Novartis' transfusional diagnostic unit. Following the refinancing process, Grifols' debt structure consists of a US Dollars 4,500 million non-current loan with institutional investors and banks segmented in two tranches (Term Loan A and Term Loan B), and a US Dollars 1,000 million bond issuance (Senior Unsecured Notes).

Non-current and current loans and borrowings are presented net of loan arrangement costs, which at 31 December 2014 amount to Euros 25 thousand for current debt (at 31 December 2013 loan arrangement costs comprised Euros 12,697 thousand non-current and Euros 881 thousand current).

The Company has extended guarantees to banks on behalf of Group companies for Euros 17,649 thousand at 31 December 2014 (Euros 35,829 thousand at 31 December 2013).

On 5 March 2014, Grifols Worldwide Operations Limited, a 100% subsidiary of Grifols, S.A., issued US Dollars 1,000 million of senior unsecured notes that will mature in 2022 and will bear annual interest at a rate of 5.25%. These notes replaced the senior unsecured notes issued in 2011 amounting to US Dollars 1,100 million, falling due in 2018 and at interest rate of 8.25%. On 29 May 2014 the notes have been admitted to listing on the Irish Stock Exchange.

Both the senior term loans and the revolving loans of the Grifols Group are secured by Grifols, S.A. and certain significant subsidiaries of Grifols, S.A. which, in conjunction with Grifols, S.A. represent, in the aggregate, at least 80% of the consolidated assets and consolidated EBITDA of Grifols, S.A. and its subsidiaries.

#### Notes to the Annual Accounts

The notes have been issued by Grifols Worldwide Operations Limited and are guaranteed on a senior unsecured basis by Grifols, S.A. and the subsidiaries of Grifols, S.A. that are guarantors and coborrower under the New Credit Facilities. The guarantors are Grifols, S.A., Biomat USA, Inc., Grifols Biologicals Inc., Grifols Shared Services North America, Inc., Grifols Diagnostic Solutions Inc., Grifols Therapeutics, Inc., Instituto Grifols, S.A. and Grifols Worldwide Operations USA, Inc.

#### (d) Trade and other payables

Details of trade and other payables are as follows:

	Euros		
	2014	2013	
	Current	Current	
Group Suppliers (note 25)	8,928,909	8,082,603	
Related parties Suppliers (note 25)	8,767,718	6,668,487	
Unrelated parties	24.022.426	26 228 824	
Suppliers Personnel	24,983,426 10,156,817	36,238,821 7,721,943	
Public entities, current tax (note 23)	30,004,299		
Public entities, other (note 23)	15,782,605	1,350,813	
Total	98,623,774	60,062,667	

- (e) Classification by maturity. The classification of financial liabilities by maturity is included in Appendix VII.
- (f) Amounts denominated in foreign currencies

The Euro value of monetary financial liabilities denominated in foreign currencies is as follows:

_			Euro	os		
			201	4		
-	US Dollar	Indian Rupee	Swiss Franc	Canadian Dollar	Argentine Peso	Total
Current payables Other financial						
liabilities Group companies	122,778	-	-	-	-	122,778
<ul> <li>– current</li> <li>Trade and other</li> <li>payables</li> </ul>	792,685	-	-	-		792,685
Suppliers Suppliers, Group	1,155,466	-	5,825	11,481		1,172,772
companies	21,975	1,303	9,795	-	27,678	60,751
Total current						
liabilities	2,092,904	1,303	15,620	11,481	27,678	2,148,986
Total financial liabilities	2,092,904	1,303	15,620	11,481	27,678	2,148,986
		,	,	,	,	

## Notes to the Annual Accounts

			2013		
	US Dollar	Japanese Yen	Brazilian Real	Thai Baht	Total
Group companies and associates, non-current	86,201,597	-	-	-	86,201,597
Total non-current liabilities	86,201,597	-	-	-	86,201,597
Current payables					
Other financial liabilities Group companies –	67,755	-	-	-	67,755
current Trade and other payables	46,349,742	-	-	-	46,349,742
Suppliers Suppliers, Group	14,575,031	-	-	-	14,575,031
companies	299,881	7,225	1,688,360	133	1,995,599
Total current liabilities	61,292,409	7,225	1,688,360	133	62,988,127
Total financial liabilities	147,494,006	7,225	1,688,360	133	149,189,724

Details of exchange differences recognised in profit or loss on financial instruments, distinguishing between settled and outstanding transactions, are as follows:

	Euros			
	201	14	2013	
	Settled	Outstanding	Settled	Outstanding
Current payables				
Loans and borrowings	(13,827,936)	(3,958,494)	1,649,679	1,270,228
Suppliers	(414,401)	(71,269)	113,250	331,806
Group companies				
Suppliers, Group companies	3,280,011	(2,421)	340,328	129,441
Total current liabilities	(10,962,326)	(4,032,184)	2,103,257	1,731,475
Total financial liabilities	(10,962,326)	(4,032,184)	2,103,257	1,731,475

# (22) Late Payments to Suppliers. "Reporting Requirement", Third Additional Provision of Law 15/2010 of 5 July 2010

Details of late payments to suppliers are as follows:

	Payments made and outstanding at the reporting date				
	2014		2013		
	Amount	%	Amount	%	
Within maximum legal period Other	(86,039,331) (37,180,743)	70% 30%	(55,540,784) (28,770,441)	66% 34%	
Total payments for the year	(123,220,074)	100%	(84,311,225)	100%	
Weighted average late payment days Late payments exceeding the maximum legal period at the	32		31		
reporting date	3,992,555	37%	2,579,134	18%	

#### Notes to the Annual Accounts

## (23) Taxation

.

Details of balances with public entities are as follows:

	Euros				
	201	4	2013		
	Non-current	Current	Non-current	Current	
Assets Deferred tax assets Current tax assets Value added tax and similar taxes	11,427,335 - - - 11,427,335	- 47,190,583 5,351,265 52,541,848	2,797,309 - - 2,797,309	- 22,340,496 7,738,524 30,079,020	
Liabilities Deferred tax liabilities Current tax liability Social Security Withholdings	3,334,193 - -	30,004,299 567,500 15,215,105	4,277,996 - -	- 439,980 910,833	
	3,334,193	45,786,904	4,277,996	1,350,813	

At 31 December 2014 the Company has recognised deferred tax assets of Euros 6,455,058 in respect of tax credits for loss carryforwards.

Also, at 31 December 2014 current tax liabilities include deferral of the payment on account.

#### Notes to the Annual Accounts

Details by company of intercompany receivables and payables resulting from the tax effect of filing consolidated tax returns are as follows:

	Euros			
	2014	2013		
	Current	Current		
Receivables (note 14)				
Laboratorios Grifols, S.A.	240,036	240,036		
Instituto Grifols,S.A.	18,522,421	-		
Logister,S.A.	864,378	66,994		
Biomat,S.A.	207,023	383,528		
Grifols International, S.A.	83,570	600,302		
Grifols Movaco,S.A.	429,586	715,223		
Grifols Viajes,S.A.	189,963	106,199		
Grifols Engineering,S.A.	884,565	65,721		
Arrahona Optimus, S.L.	265,325	44,986		
Diagnostic Grifols, S.A.	1,222,379	-		
Gri-Cel, S.A.	266,572	249,107		
	23,175,818	2,472,096		
Payables (note 21)				
Biomat. S.A.	181,429	131,933		
Grifols Viajes, S.A	119,580	12.673		
Instituto Grifols,S.A.	14,258,115	22,741,675		
Diagnostic Grifols,S.A.	3,143,241	7,988,410		
Laboratorios Grifols,S.A.	2,809,357	1,814,569		
Grifols Movaco, S.A	834,970	1,474,422		
Grifols Engineering,S.A.	776,582	987,493		
Logister, S.A.	112,894	147,226		
Grifols International.S.A.	4,549,619	1,945,959		
Arrahona Optimus, S.L.	46,305	46,499		
Gri-Cel S.A	16,992	812,622		
		· · · · · ·		
	26,849,084	38,103,481		

Balances receivable and payable at 31 December 2014 and 2013 comprise accrued income tax and value added tax.

The Company has the following main applicable taxes open to inspection by the Spanish taxation authorities:

Тах	Years open to inspection
Income tax	2010-2014
Value added tax	2010-2014
Personal income tax	2010-2014
Capital gains tax	2011-2014
Tax on economic activities	2011-2014
Social Security	2011-2014
Non-residents tax	2010-2014
Customs duties	2011-2014

#### Notes to the Annual Accounts

Tax inspections on income tax, withholdings and VAT for 2010, 2011 and 2012 were initiated in Instituto Grifols, S.A and Grifols Movaco, S.A in July 2014. Due to the treatment permitted by fiscal legislation of certain transactions, additional tax liabilities could arise in the event of inspection. In any case, the Company's directors do not consider that any such liabilities that could arise would have a significant effect on the annual accounts.

#### (a) Income tax

The Company files consolidated tax returns with Instituto Grifols, S.A., Laboratorios Grifols, S.A., Diagnostic Grifols, S.A., Grifols Movaco, S.A., Biomat, S.A., Logister, S.A., Grifols International, S.A., Grifols Engineering, S.A., Grifols Viajes, S.A., Arrahona Optimus, S.L. and Gri-Cel, S.A.

A reconciliation of net income and expenses for the year with the taxable income is provided in Appendix IX.

The relationship between the tax income and accounting profit for the year is shown in Appendix X.

Details of the tax income recognised in the income statement are as follows:

	Euros		
	2014	2013	
Current tax			
Present year	(27,719,904)	(21,056,546)	
	(27,719,904)	(21,056,546)	
Deferred tax			
Source and reversal of temporary differences			
Property, plant and equipment	(814,009)	(732,925)	
Investments	-	(238,909)	
Finance costs	-	2,677,792	
Cost of reducing deferred tax assets recognised in			
prior years	-	2,410,984	
Provisions	500,000	-	
Tax rate adjustment Deductions generated	46,304 (1,748,561)	- (1,616,029)	
Deductions applied	4,876	1,480,635	
Adjustment of deductions in prior years	(136,778)	(467,092)	
Adjustment of deferred tax assets and liabilities	(37,129)	148,682	
	(29,905,201)	(17,393,408)	

#### Notes to the Annual Accounts

	Euros					
	Assets Liabilities		ities	Net		
	2014	2013	2014	2013	2014	2013
Property, plant and equipment Grants Investments in	755,590 -	402,942 -	(2,873,454) (26,514)	(3,725,109) (31,817)	(2,117,864) (26,514)	(3,322,167) (31,817)
Group companies Hedging derivatives	-	- 287,054	(434,225) -	(521,070) -	(434,225) -	(521,070) 287,054
Tax credits for tax loss carryforwards Rights to tax deductions and credits	6,455,058 4,216,687	- 2,107,313	-		6,455,058 4,216,687	- 2,107,313
Total assets/liabilities	11,427,335	2,797,309	(3,334,193)	(4,277,996)	8,093,142	(1,480,687)

Details of deferred tax assets and liabilities by type of asset and liability are as follows:

In 2013 deferred tax assets and liabilities totalling Euros 291,170 were adjusted in the 2012 income tax settlement.

Details of deferred tax assets and liabilities that are expected to be realised or reversed in periods exceeding 12 months are as follows:

	Euros		
	2014	2013	
Deferred tax assets relating to temporary differences	671,125	397,779	
Total assets	671,125	397,779	
Deferred tax liabilities	3,104,073	3,884,375	
Net	(2,432,948)	(3,486,596)	

#### (b) Value added tax

Since 1 January 2008 the Company has filed consolidated tax returns with Instituto Grifols, S.A., Laboratorios Grifols, S.A., Diagnostic Grifols, S.A., Grifols Movaco, S.A., Biomat, S.A., Logister, S.A., Grifols International, S.A., Grifols Engineering, S.A., Grifols Viajes, S.A., Arrahona Optimus, S.L. and Gri-Cel, S.A. (the latter two since 1 January 2009).

#### Notes to the Annual Accounts

#### (24) Environmental Information

Details at 31 December of property, plant and equipment used to minimise the Company's impact on the environment are as follows:

	Euros		
		2014	
		Accumulated	
Description	Cost	depreciation	Net
Sewage treatment	126,162	(37,356)	88,806
Water saving	311,021	(167,660)	143,361
Electricity saving	1,237,578	(276,182)	961,396
Waste management	243,427	(230,040)	13,387
	1,918,188	(711,238)	1,206,950
		2013	
Sewage treatment	126,162	(24,740)	101,422
Water saving	311,021	(140,779)	170,242
Electricity saving	544,443	(65,158)	479,285
Waste management	243,427	(221,458)	21,969
	1,225,053	(452,135)	772,918

Environmental expenses amount to Euros 99,953 in 2014 (Euros 76,936 in 2013).

#### (25) Related Party Balances and Transactions

(a) Related party balances

Details of balances receivable from and payable to Group companies and related parties and the main characteristics are disclosed in notes 14 and 21.

Details of balances by category are provided in Appendix XI.

(b) Related party transactions

Details of the Company's transactions with related parties are provided in Appendix XII.

Services are normally negotiated with Group companies to include a mark-up of between 5% and 10%.

The Company contributes 0.7% of pre-tax consolidated profits for each year to a non-profit organisation.

During 2013 the Company carried out a loan of treasury stock with a related party (see note 18).

Transactions with other related parties are conducted at arm's length.

#### Notes to the Annual Accounts

(c) Information on the Company's directors and senior management personnel

In 2014 the independent members of the Company's board of directors accrued Euros 650 thousand in their capacity as such (Euros 600 thousand in 2013). Directors representing shareholders' interests received remuneration of Euros 100 thousand in 2014 (Euros 100 thousand in 2013). The members of the Company's board of directors who have a labour relationship with the Company and senior management personnel received total remuneration of Euros 3,881 thousand and Euros 5,586 thousand, respectively (Euros 3,705 thousand and Euros 5,104 thousand in 2013). Members of the board of directors have not received any loans or advances nor has the Company extended any guarantees on their behalf. The Company has no pension or life insurance obligations with its former or current directors or senior management personnel. In addition, termination benefit commitments are in place for certain Company directors and senior management personnel (see note 19).

(d) Conflicts of interest concerning the directors

The Company's directors and their related parties, have not entered into any conflict of interest that should have been reported in accordance with article 229 of the revised Spanish Companies Act.

#### (26) Income and Expenses

(a) Revenues

Details of revenues by category of activity and geographical market are shown in Appendix XIII.

(b) Supplies

Details of other supplies used are as follows:

	Euros		
	2014	2013	
Other supplies used Purchases of spare parts Impairment of merchandise Change in inventories	3,516,271 6,504 (2,505,104)	644,193 47,369 (73,576)	
	1,017,671	617,986	

In 2014 the Company executed projects on behalf of other companies, with a cost of Euros 857 thousand (Euros 1,739 thousand in 2013).

(c) Employee benefits expense and provisions

Details of employee benefits expense are as follows:

	Euros	Euros		
	2014	2013		
Employee benefits expense Social Security payable by the Company Defined contribution plan contributions Other employee benefits expenses	5,320,496 88,364 1,236,416	4,323,748 79,992 1,030,229		
Annual contributions	13,512	11,654		
	6,658,788	5,445,623		

#### Notes to the Annual Accounts

#### (27) Employee Information

The average headcount of the Company, distributed by department, is as follows:

	Number		
	2014	2013	
Technical area Administration and other General management Marketing	60 323 31 7	48 282 27 6	
	421	363	

At 31 December 2014 and 2013 the distribution by gender of Company personnel and the members of the board of directors is as follows:

	Number			
	2014		2013	
	Female	Male	Female	Male
Technical area	58	7	50	5
Administration and other	128	223	106	186
General management	19	15	16	12
Marketing	4	3	3	3
Directors	3	10	2	10
	212	258	177	216

#### (28) Audit Fees

KPMG Auditores, S.L., the auditors of the Company's annual accounts, have invoiced the Company the following fees and expenses for professional services during the years ended 31 December 2014 and 2013:

	Euros		
	2014 2013		
Audit services Other assurance services Other services	1,554,200 285,025 -	1,084,200 86,678 243,909	
	1,839,225	1,414,787	

The amounts in the above table include the total fees for services rendered in 2014 and 2013, irrespective of the date of invoice.

Audit services include the audit under PCAOB of the financial statements prepared in accordance with IFRS-IASB and limited review services for the interim financial statements prepared in accordance with IFRS-IASB. In addition, they include audit services subject to the Spanish Audit Law, amounting to 310,200 euros (185,200 euros in 2013).

#### Notes to the Annual Accounts

#### (29) Events After the Reporting Period

The Company has repurchased industrial assets in Spain for a total amount of Euros 44 million. The Company has exercised the options to purchase assets at fair value included in the corresponding sale and leaseback agreements (see note 7).

# GRIFOLS, S.A. Details of intangible assets and movement for the year ended 31 December 2014 (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Computer software	Emission allowances	Advances	Total
Cost at 1 January 2014	25,876,997	82,130	0	25,959,127
Additions	2,734,572	-	2,619,946	5,354,518
Disposals	(97,017)	-	-	(97,017)
Irreversible impairment losses	-	40,726	-	40,726
Cost at 31 December 2014	28,514,552	122,856	2,619,946	31,257,354
Accumulated amortisation at 1 January 2014	(20,738,878)	-	-	(20,738,878)
Additions	(1,709,574)	-	-	(1,709,574)
Disposals	97,016	-	-	97,016
Accumulated amortisation at 31 December 2014	(22,351,436)	0	0	(22,351,436)
Carrying amount at 31 December 2014	6,163,116	122,856	2,619,946	8,905,918

This appendix forms an integral part of note 5 to the annual accounts, in conjunction with which it should be read

APPENDIX I (2 of 2)

# GRIFOLS, S.A.

# Details of intangible assets and movement for the year ended 31 December 2013 (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Computer	Emission		
	software	allowances	Advances	Total
Cost at 1 January 2013	22,083,276	235,462	131,465	22,450,203
Additions	3,754,959	-	-	3,754,959
Disposals	-	(238,460)	(131,465)	(369,925)
Transfers	38,762	-	-	38,762
Irreversible impairment losses	-	85,128	-	85,128
Cost at 31 December 2013	25,876,997	82,130	0	25,959,127
Accumulated amortisation at 1 January 2013	(19,399,718)	-	-	(19,399,718)
Additions	(1,339,160)	-	-	(1,339,160)
Disposals	-	-	-	0
Accumulated amortisation at 31 December 2013	(20,738,878)	0	0	(20,738,878)
Carrying amount at 31 December 2013	5,138,119	82,130	0	5,220,249

This appendix forms an integral part of note 5 to the annual accounts, in conjunction with which it should be read

#### Details of Property, Plant and Equipment and Movement for the year ended 31 December 2014 (Expressed in euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

		Other	Euros		
	Technical installations and machinery	installations, equipment and furniture	Under construction and advances	Other items	Total
Cost at 1 January 2014	7,231,022	10,992,326	5,027,906	8,048,205	31,299,459
Additions	41,263	329,239	471,618	2,524,299	3,366,419
Disposals	(2,898)	(171,727)		(63,801)	(238,426)
Transfers	626,446	599,537	(4,387,138)	217,700	(2,943,455)
Cost at 31 December 2014	7,895,833	11,749,375	1,112,386	10,726,403	31,483,997
Accumulated depreciation at 1 January 2014	(4,309,511)	(6,715,976)		(5,253,235)	(16,278,722)
Additions	(710,903)	(813,816)		(1,274,030)	(2,798,749)
Disposals	990	169,499		63,802	234,291
Accumulated depreciation at 31 December 2014	(5,019,424)	(7,360,293)	0	(6,463,463)	(18,843,180)
Carrying amount at 31 December 2014	2,876,409	4,389,082	1,112,386	4,262,940	12,640,817

This appendix forms an integral part of note 6 to the annual accounts, in conjunction with which it should be read

#### Details of Property, Plant and Equipment and Movement for the year ended 31 December 2013 (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Euros								
	Technical installations and machinery	Other installations, equipment and furniture	Under construction and advances	Other items	Total				
Cost at 1 January 2013	6,701,091	10,569,757	3,774,018	6,285,164	27,330,030				
Additions	42,120	282,421	1,366,233	1,761,430	3,452,205				
Disposals	0	(637)	0	(468)	(1,105)				
Transfers	487,811	140,785	(112,346)	2,079	518,329				
Cost at 31 December 2013	7,231,022	10,992,326	5,027,906	8,048,205	31,299,459				
Accumulated depreciation at 1 January 2013	(3,638,508)	(5,941,568)	0	(4,551,047)	(14,131,123)				
Additions	(671,003)	(775,045)	0	(702,656)	(2,148,704)				
Disposals	0	637	0	468	1,105				
Accumulated depreciation at 31 December 2013	(4,309,511)	(6,715,976)	0	(5,253,235)	(16,278,722)				
Carrying amount at 31 December 2013	2,921,511	4,276,350	5,027,906	2,794,970	15,020,737				

This appendix forms an integral part of note 6 to the annual accounts, in conjunction with which it should be read

# GRIFOLS, S.A. Information on Group companies 31 December 2014 (Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

Name	Registered offices	Activity	9 Dir	% ownership Ind	Total	Share capital	Reserves	Other equity items	Interim dividend	Profit/(loss) for the year	Total equity	Carrying amount of investment	Dividends received in 2014
TiGenix N.V.	Belgica	Investigación	Dii	21.300	21.300	16.048.000	32,443,000		uividerid	(9,151,000)	39,340,000		
Meckwins, S.I	España	Investigación		9.350	9.350	72.000	1.574.248			-18.328.00	1.627.920		
Aradigm Corporation	EE.UU.	Investigación	35.000	0.000	35.000		25,049,719	3,676,494		3,226,673	31,952,887	20,635,872	
Nanotherapix, S.L.	España	Investigación		51.000	51.000	6,139	4,121,505			(1,569,185)	2,558,459		
VCN Biosciences, S.L.	España	Investigación		49.450	49.450	56,268	27,537			(1,249,116)	(1,165,311)		
Kiro Robotics S.L	España	Investigación	50.000		50.000	4,000,000	19,000,000			(816,239)	22,183,761	22,153,050	
Progenika Inc	EE.UU.	Industrial		56,150	56.150	758	(3,648,233)	(634,916)		1,442,980	(2,839,411)		
Progenika Latina ,S.A. de CV	México	Industrial		56.150	56.150	3,813,302	(3,687,337)	31,525		(420,130)	(262,640)		
Brainco Biopharma, S.L	España	Industrial		28,423	28,423	3.000	(256,340)			(449,158)	(702,498)		
Abyntek Biopharma, S.L	España	Industrial		43.763	43.763	3,002	(335,791)			(56,391)	(389,180)		
Proteomika, S.L.U	España	Industrial		56.150	56.150	79,060	2,810,257			(343,703)	2,545,614		
Progenika Biopharma, S.L	España	Industrial	56.150		56.150	615,374	8,427,138			1,002,986	10,045,498	65,353,850	
Asociación I+D Progenika	España	Industrial		56.150	56.150	106,000	(7,220)			(4,512)	94,268		
Instituto Grifols, S.A.	España	Industrial	99.998	0.002	100.000	1,537,989	44,866,665			97,969,642	144,374,296	1,537,990	39,999,218
Diagnostic Grifols,s.A.	España	Industrial	99.998	0.002	100.000	336,560	16,403,093			5,575,607	22,315,260	336,561	
Grifols Movaco,S.A.	España	Comercial	99.999	0.001	100.000	2,404,601	1,783,368			(1,163,319)	3,024,650	3,904,619	
Logister,S.A.	España	Servicios	99.998	0.002	100.000	105,325	(306,587)			187,058	(14,204)	105,297	
Laboratorios Grifols, S.A.	España	Industrial	99.998	0.002	100.000	21,798,360	(213,523)			(7,035,790)	14,549,047	40,798,366	
Biomat,S.A.	España	Industrial	99.900	0.100	100.000	60,110	711,484			475,184	1,246,778	60,041	686,300
Grifols International, S.A.	España	Servicios		100.000	100.000	2,860,154	10,364,170			(12,831,088)	393,236		
Grifols Engineering, S.A.	España	Industrial	99.950	0.050	100.000	60,120	1,008,548			1,801,219	2,869,887	60,090	999,500
Grifols Viajes,S.A.	España	Servicios	99.900	0.100	100.000	60,110	738,633			(76,623)	722,120	60,041	
Arrahona Optimus,S.L.	España	Servicios	99.995	0.005	100.000	1,925,100	1,656,981			167,456	3,749,537	3,551,251	
Gri-Cel, S.A.	España	Investigación	0.001	99.999	100.000	15,060,102	(1,050,682)			(4,273,328)	9,736,092	1	
Araclon Biotech, S.L.	España	Investigación		66.150	66.150	8,871	7,075,504			(6,803,779)	280,596		
Grifols Worldwide Operations USA													
Inc.	EE.UU.	Industrial		100.000	100.000	1		19,789		678,634			
Grifols Chile,S.A.	Chile	Comercial	99.000		99.000	385,453	16,257,047	(280,654)		1,592,000	17,953,846	385,454	
Grifols Argentina,S.A.	Argentina	Comercial	95.010	4.990	100.000	955,675	10,836,633	(6,182,203)		4,327,790	9,937,895	6,563,003	
Logística Grifols,S.A. de CV	México	Servicios	99.990	0.010	100.000	92,279	2,276,408	206,143		254,010	2,828,840	235,258	-
Grifols Portugal Productos													
Farmacéutiocs e Hospitalares,Lda.	Portugal	Comercial	0.010	99.990	100.000	511.806	1,224,511			1.949.612	3,685,929		
Grifols, s.r.o.	República Checa		100.000	99.990	100.000	51,806	10.049.686	(384.929)		854.309	10.570.663	51.600	
Grifols USA, LLC	EE.UU.	Comercial	100.000	100.000	100.000	561,686	(4,718,077)	7,058,772		65,750,461	68,652,842	000,10	
Grifols UK,Ltd.	Reino Unido	Comercial	100.000	100.000	100.000	4,285	10,809,907	220,665		740,613	11,775,470	21,167,620	
Grifols Italia,S.p.A.	Italia	Comercial	100.000		100.000	2,496,000	4,481,157	220,005		50,415	7,027,572	12,862,540	
Grifols Brasil.Ltda.	Brasil	Comercial	100.000		100.000	8,279,020	(753,022)	112,537		(700,541)	6,937,994	8,279,017	
Grifols France S.A.R.L	Francia	Comercial	99.990	0.010	100.000	657,734	(324,513)	112,007		(158,756)	174.465	657,657	
Squadron Reinsurance Ltd.	Ireland	Servicios	55.550	100.000	100.000	635,001	27,885,530	(1)		6,066,707	34,587,237	037,037	
Biomat USA.Inc.	FEUU	Industrial		100.000	100.000	035,001	145,289,366	1.692.743		30,986,008	177,968,117		
Grifols Biologicals, Inc.	EE.UU.	Industrial		100.000	100.000		274,604,602	22,707,974		7,350,588	304,663,164		
Grifols Shared Services North	EE.00.	muustnai		100.000	100.000		274,004,002	22,101,914		7,330,300	304,003,104		
America. Inc.													
(anteriormente Grifols Inc.)	EE.UU.	Servicios	100.000		100.000		665.435.497	128.396.847		(224,579,242)	569.253.102	1.026.005.280	
Grifols Asia Pacific Pte. Ltd.	Singapur	Comercial	100.000		100.000	362.387	9.421.879	510,499		2.275.460	12.570.225	714,769	
Grifols (Thailand), Ltd.	Tailandia	Comercial	100.000	48.000	48.000	61,198	2,939,011	396,393		2,275,460 366,167	3,762,769	/ 14,709	-
	Malasia	Comercial		30.000	30.000	30.283	2,939,011			230.821	1.301.220		
Grifols Malaysia Sdn Bhd				30.000				50,616				40 744	-
Grifols Polska, Sp.z.o.o.	Polonia	Comercial Industrial	100.000	100.000	100.000 100.000	10,714 15,241	2,189,637	136,387		(8,339)	2,328,399	10,714	
Plasmacare,Inc.	EE.UU.	Industrial					17,542,377	1,518,599		819,903	19,896,120		
Grifols México,S.A. de CV Grifols Australia Pty I td	México Australia	Industrial	99.990 100.000	0.010	100.000 100.000	461,397 1.695.072	7,640,539 7,741,467	(341,368) (1,153,677)	-	1,980,945 (2,131,563)	9,741,513 6,151,299	461,224 34,974,212	-
Medion Diagnostic Grifols AG	Suiza	Industrial	80.000		80.000	2,487,150	(3,708,937)	(222,364)		(1,153,296)	(2,597,447)	1,989,720	
Medion Diagnostic GmbH	Alemania	Comercial		80.000	80.000	1,500,000	(1,005,873)	(107 701)		(470.040)	494,127		-
Grifols Colombia, Ltda.	Colombia	Comercial	99.000	1.000	100.000	822,563	117,184	(107,731)		(472,840)	359,176	822,182	
Grifols Nordic AB	Suecia	Comercial	100.000		100.000	10,392	686,260	(34,637)		271,881	933,896		
GRI-CEI, S.A Productos para	Deeeil	la du atai al	00.000		co occ	E ECE 001	(05.000)	(4 4 4 7 0 * *		(40.041)	4 000 000	0.000.000	
transfusao	Brasil	Industrial Comercial	60.000 100.000		60.000 100.000	5,565,901	(65,686)	(1,147,044)	-	(49,941)	4,303,230	3,339,638	
Grifols Deutschland, GmbH	Alemania					25,000	25,841,193	(726,953)		6,375,537	31,514,777	12,664,559	
Grifols Therapeutic Inc.	EE.UU.	Industrial		100.000	100.000	12,686,461	1,865,371,548	252,645,320		104,246,657	2,234,949,986		
Talecris Plasma Resources Inc.	EE.UU.	Industrial		100.000	100.000	7	(20,806,459)	9,377,932		4,942,198	(6,486,322)		-
Grifols Canadá, Ltd.	Canadá	Industrial		100.000	100.000	6	1,113,087	283,318		3,951,021	5,347,432		
Grifols Worldwide Operations			100.005		400.00-		F0 000 ····	05 000 5	(000 000 0	000 005 7	4 40 000 7	50 505	
Limited	Irlanda	Industrial	100.000		100.000	1	53,830,438	35,096,567	(230,000,000)	289,695,742	148,622,748	56,505,381	230,000,000
Grifols Pharmaceutical Consulting	Ohina	Commin	400.000		400.000	4 000 000	(FF 077	04.005		200.000	4 000 051	4 000 000	
(Shanghai) Co, Ltd	China	Comercial	100.000		100.000	1,000,000	(55,257)	81,625		309,983	1,336,351	1,000,000	
Grifols Switzerland, AG	Suiza	Comercial	100.000		100.000	81,189		72,410		7,173,999	7,327,598	81,189	-
Grifols Diagnostics Solutions Inc													
(anteriormente G-C Diagnostics													
Corp.)	EE.UU.	Industrial	100.000		100.000	37	293,793,610	38,315,689		24,004,694	356,114,030	293,793,647	
Grifols (H.K.), Limited	Hong Kong	Comercial		100.000	100.000	37,899,376	(7,019,973)	4,310,058		5,716,878			
Grifols Japan KK	Japon	Comercial	100.000		100.000	354,409	354,409	(18,366)		26,059		708,818	
Grifols Beijing	China	Comercial		100.000	100.000			(3,705)		(187,830)			
Grifols India Healthcare Private Ltd	India	Comercial	99.990	0.010	100.000					-		1,299	

This appendix forms an integral part of note 12 to the annual accounts, in conjunction with which it should be read

# Appendix III (2 of 2)

---

#### GRIFOLS, S.A.

#### Information on Group companies 31 December 2013

# (Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

Name	Registered offices	Activity	% Dir	ownership Ind	Total	Share capital	Reserves	Other equity items	Interim dividend	Profit/(loss) for the year	Total equity	Carrying amount of investment	Dividen received 2013
igenix	Belgium	Research		21.300	21.3			Other equity items	Intenin dividend	uie yeai	Total equity		
leckwins, S.L	Spain	Research		14.038	14.0	5,400.00	671,086			-20,757.00	655,729		
radigm Corporation	United States	Research	35.000		35.0	0,100.00	23,316,095	(1,025,308)		2,070,753.25	24,361,540	20,635,872	
			00.000					(1,020,000)				20,000,012	
anotherapix, S.L.	Spain	Research		51.000		5,513	4,186,567			(1,536,632)	2,655,448		
N Biosciences, S.L.	Spain	Research		40.000	40.0	1,690,592	(1,365,584)			(941,222)	(616,214)		
ogenika Inc	United States	Industrial		56.150	56.2	758	(3,228,971)	(214,144)		(419,262)	(3,861,619)		
ogenika Latina ,S.A. de CV	Mexico	Industrial		56.150	56.2	3,813,302	(3,108,426)	14,681		(578,911)	140,646		
eventia 2,0 Genetics, S.L	Spain	Industrial		56.150	56.2	819,293	(548,806)			(131,227)	139,260		
ainco Biopharma, S.L	Spain	Industrial		28.423	28.4	6,253,006	43,423			(1,386,924)	4,909,505		
yntek Biopharma, S.L	Spain	Industrial		43,763	43.8	333,600	(539,374)			(68,938)	(274,712)		
oteomika, S.L.U	Spain	Industrial		56.150	56.2	79,060	4,606,069			(1,795,812)	2,889,317		
ogenika Biopharma, S.L	Spain	Industrial	56.150		56.2	615,374	18,229,242			(9,649,042)	9,195,574	65,353,850	
ociación I+D Progenika	Spain	Industrial		56.150	56.2	66,000	(65,216)			57,996	58,780	00,000,000	
	Spain	Industrial	99,998	0.002	100.0				(00,000,000)	133.352.413		1.537.990	190.403
stituto Grifols, S.A.						1,537,989	41,514,252		(90,000,000)		86,404,654		
agnostic Grifols,s.A.	Spain	Industrial	99.998	0.002	100.0	336,560	13,729,760			2,673,333	16,739,653	336,561	3,999,9
ifols Movaco,S.A.	Spain	Commercial	99.999	0.001	100.0	2,404,601	(3,709,004)			3,992,372	2,687,969	2,404,619	
gister,S.A.	Spain	Services	99.998	0.002	100.0	105,325	272,335			(578,922)	(201,262)	105,297	
ooratorios Grifols,S.A.	Spain	Industrial	99.998	0.001	100.0	21,798,360	(1,990,123)	(965)		(5,222,435)	14,584,837	33,798,366	
mat,S.A.	Spain	Industrial	99.900	0.100	100.0	60,110	711,484			686,987	1,458,581	60,041	164,19
ifols International,S.A.	Spain	Services	99,900	0.100	100.0	2,860,154	1,121,001			(5,756,831)	(1,775,676)	(60)	
ifols Engineering,S.A.	Spain	Industrial	99.950	0.050	100.0	60,120	878,378			1,130,170	2,068,668	60,090	
ifols Viajes,S.A.	Spain	Services	99.900	0.100	100.0	60,110	728,593			10,039	798,742	60,041	
rahona Optimus,S.L.	Spain	Services	99.900	0.010	100.0	1,925,100	1,536,014			120,967	3,582,081	3,551,251	
i-Cel. S.A.	Spain	Research		99,999	100.0	15,060,102	812.042			(1.862,725)	3,582,081	3,001,201	
			0.001										
aclon Biotech, S.L.	Spain	Research		61.400	61.4	7,703	7,197,446			(5,117,739)	2,087,410		
ifols Chile,S.A.	Chile	Commercial	99.000		99.0	385,453	14,959,636	(30,297)		1,297,411	16,612,203	385,454	
ifols Argentina,S.A.	Argentina	Commercial	95.010	4.990	100.0	955,675	9,655,058	(5,397,887)		1,181,575	6,394,421	6,563,003	
gística Grifols,S.A. de CV	Mexico	Services	99.990	0.010	100.0	92,279	1,890,369	166,810		386,039	2,535,497	235,258	
ifols Portugal Productos													
rmacéutiocs e													
ospitalares,Lda.	Portugal	Commercial	0.010	99.999	100.0	478,255	5,091,565	33,551		(3,867,055)	1,736,316		
ifols, s.r.o.	Czech Republic	Commercial	100.000	33.333	100.0	51,597	9,164,844	(273,107)		884,841	9,828,175	51,600	
												51,600	
ifols USA, LLC	United States	Commercial		100.000	100.0	561,686	(716,921)	326,821		(4,001,156)	(3,829,570)		
ifols UK,Ltd.	United Kingdom	Commercial	100.000		100.0	4,285	10,825,552	(539,062)		(15,644)	10,275,131	21,167,620	
ifols Italia,S.p.A.	Italy	Commercial	100.000		100.0	2,494,762	8,918,982	(30,410)		(4,406,177)	6,977,157	12,862,540	
ifols Brasil,Ltda.	Brazil	Commercial	100.000		100.0	4,335,098	(3,828,597)	(86,548)		3,075,575	3,495,528	4,335,095	
ifols France,S.A.R.L.	France	Commercial	99.990	0.010	100.0	657,734	(259,909)	(2)		(64,602)	333,221	657,657	
omat USA,Inc.	United States	Industrial		100.000	100.0		124,282,394	(19,250,114)		21,006,973	126,039,253		
uadron Reinsurance Ltd.	Ireland	Services		100.000	100.0	635,001	44.336.000	(,=,,	(20,500,000)	4.049.530	28,520,531		20.500.0
ifols Biologicals, Inc.	United States	Industrial		100.000	100.0		217,571,304	(14,706,315)	(20,000,000)	57,033,298	259,898,287		
ifols,Inc.	United States	Services	100.000	100.000	100.0		841,668,001	44,312,325		(176,232,504)	709,747,822	1,026,005,280	
fols Asia Pacific Pte. Ltd.	Singapore	Commercial	100.000		100.0	362,387	8,717,886	(927,439)		703,993	8,856,827	714,769	7,624,8
ifols (Thailand), Ltd.	Thailand	Commercial		48.000	48.0	61,198	2,988,614	(26,408)		(35,314)	2,988,090		
ifols Malaysia Sdn Bhd	Malaysia	Commercial		30.000	30.0	30,283	883,091	(18,005)		106,409	1,001,778		
fols Polska, Sp.z.o.o.	Poland	Commercial	100.000		100.0	10,714	1,848,490	200,146		341,147	2,400,497	10,714	
ismacare,Inc.	United States	Industrial		100.000	100.0	15,241	17,455,756	(824,204)		86,621	16,733,414		
fols México,S.A. de CV	Mexico	Industrial	99.990	0.010	100.0	461,397	5,231,714	(385,694)		2,408,826	7,716,243	461,224	
fols Australia Pty Ltd	Australia	Industrial	100.000		100.0	1,695,072	10,260,326	(1,561,040)		(2,518,859)	7,875,499	34,974,212	
dion Diagnostic Grifols AG	Switzerland	Industrial	80.000		80.0	2,487,150	(2,163,399)	(182,774)		(1,545,539)	(1,404,562)	1,989,720	
dion Diagnostic GmbH	Germany	Commercial		80.000	80.0	1,500,000	(1,005,873)	(102,114)		(1,545,555)	494,127	.,505,720	
								(0.000)				7 050	
fols Colombia, Ltda.	Colombia	Commercial	99.000	1.000	100.0	8,234	39,985	(8,868)		77,199	116,550	7,852	
ols Nordic AB	Sweden	Commercial	100.000		100.0	10,392	1,104,815	(3,841)		(418,555)	692,811		
I-CEI, S.A Producto transfusao	Brazil	Industrial	60.000		60.0	5,565,901	(53,792)	(1,198,362)		(11,893)	4,301,854	3,339,638	
ols Deutschland,GmbH	Germany	Commercial	100.000		100.0	15,000	18,281,320	(314,615)		7,642,195	25,623,900	12,664,559	
ols Therapeutic Inc.	United States	Industrial		100.000	100.0	12,686,461	971,741,970	(14,551,660)		371,281,353	1,341,158,124		
ecris Plasma Resources Inc.	United States	Industrial		100.000	100.0	7	(21,911,151)	10,385,327		845,997	(10,679,820)		
ols Canadá, Ltd. ols Worldwide Operations	Canada	Industrial		100.000	100.0	6	980,821	(65,283)		132,266	1,047,810	-	
ited ols Pharmaceutical	Ireland	Industrial	100.000		100.0	1	56,505,380	(2,358,343)		(2,674,942)	51,472,096	56,505,381	
nsulting (Shanghai) Co, Ltd	China	Commercial	100.000		100.0	400,000		(5,320)		(55,257)	339,423	400,000	_
								(0,320)		(55,257)			
ifols Switzerland, AG	Switzerland	Industrial	100.000			81,189					81,189	81,189	
C Diagnostic Corp.	United States	Industrial	100.000										
ecris Biotherapeutics erseas Services, Corp.	EE.UU.												

This appendix forms an integral part of note 12 to the annual accounts, in conjunction with which it should be read

APPENDIX IV 1 of 2

#### GRIFOLS, S.A.

#### **Classification of Financial Assets by Category** for the year ended 31 December 2014

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

		Non-current			Current		
	At amortised cos	st or cost	-	At amortised co	st or cost		
	Carrying amount	Fair value	Total	Carrying amount	Fair value	Total	
Loans and receivables							
Fixed rate			0	198,934,765	198,934,765	198,934,765	
Variable rate	16,410,455	16,410,455	16,410,455			0	
Tax effect			0	23,175,818	23,175,818	23,175,818	
Deposits and guarantees	839,307	839,307	839,307	8,802	8,802	8,802	
Other Trade receivables			0	68,284	68,284	68,284	
Trade receivables			0	32,882,693	32,882,693	32,882,693	
Other receivables	3,294,621	3,294,621	3,294,621	11,410	11,410	11,410	
Total	20,544,383	20,544,383	20,544,383	255,081,772	255,081,772	255,081,772	
Total financial assets	20,544,383	20,544,383	20,544,383	255,081,772	255,081,772	255,081,772	

This appendix forms an integral part of note 13 to the annual accounts, in conjunction with which it should be read.

APPENDIX IV 2 of 2

#### GRIFOLS, S.A.

# Classification of Financial Assets by Category for the year ended 31 December 2013

(Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

		Non-current			Current	
	At amortised cos	st or cost	_	At amortised co		
	Carrying amount	Fair value	Total	Carrying amount	Fair value	Total
Loans and receivables						
Fixed rate			0			
Variable rate	18,158,520	18,158,520	18,158,520	536,315,839	536,315,839	536,315,839
Tax effect			0	2,472,096	2,472,096	2,472,096
Deposits and guarantees	811,793	811,793	811,793	15,573	15,573	15,573
Other Trade receivables			0	631,923	631,923	631,923
Trade receivables			0	12,750,006	12,750,006	12,750,006
Other receivables	2,900,442	2,900,442	2,900,442	8,827	8,827	8,827
Total	21,870,755	21,870,755	21,870,755	552,194,264	552,194,264	552,194,264
Total financial assets	21,870,755	21,870,755	21,870,755	552,194,264	552,194,264	552,194,264

This appendix forms an integral part of note 13 to the annual accounts, in conjunction with which it should be read.

APPENDIX V 1 of 2

#### GRIFOLS, S.A.

#### Details of Reserves and Results and movement for the year ended 31 December 2014 (Expressed in Euros)

(Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

			Euros		
	Legal and statutory reserves	Differences on translation of capital to Euros	Voluntary reserves	Profit for the year	Total
Balance at 1 January 2014	23,576,478	3,020	150,934,337	168,350,884	342,864,719
Recognised income and expense				205,197,369	205,197,369
Distribution of profit for 2013					
Appropriation to legal reserves Reserves Preferred dividend	344,263  	 	 29,188,512 	(344,263) (29,188,512) (1,307,126)	0 0 (1,307,126)
Interim dividend Other movements (Note 12)		0 0		(68,755,491) (68,755,492)	(68,755,491) (68,755,492)
Balance at 31 December 2014	23,920,741	3,020	180,122,849	205,197,369	409,243,979

This appendix forms an integral part of note 18 to the annual accounts, in conjunction with which it should be read.

APPENDIX V 2 of 2

#### GRIFOLS, S.A.

#### Details of Reserves and Results and movement for the year ended 31 December 2013 (Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

		Euros								
	Legal and statutory reserves	Differences on translation of capital to Euros	Voluntary reserves	Profit for the year	Total					
Balance at 1 January 2013	21,323,219	3,020	87,425,262	52,369,156	161,120,657					
Recognised income and expense				168,350,884	168,350,884					
Distribution of profit for 2012										
Appropriation to legal reserves	2,253,259			(2,253,259)	0					
Reserves			48,808,771	(48,808,771)	0					
Preferred dividend				(1,307,126)	(1,307,126)					
Acquisition of treasury stock					0					
Disposal of treasury stock			11,806,429		11,806,429					
Capital increase			(2,036,132)		(2,036,132)					
Interim dividend			924,627		924,627					
Other movements (Note 12)			4,005,380		4,005,380					
Balance at 31 December 2013	23,576,478	3,020	150,934,337	168,350,884	342,864,719					

This appendix forms an integral part of note 18 to the annual accounts, in conjunction with which it should be read.

#### Details of Financial Liabilities by Category for the year ended 31 December 2014 (Expressed in Euros)

(Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

		Non- Cur	rent		Current			
	At amortised cos	st or cost			At amortised cos	st or cost		
	Carrying amount	Fair value	At fair value	Total	Carrying amount	Fair value	Total	
Other liabilities at fair value through profit or loss								
Derivative financial instruments (note 15)			0	0			0	
Total	0	0	0	0	0	0	0	
Debts and payables								
Loans, Group companies	409,536,410	409,536,410		409,536,410	230,380,846	230,380,846	230,380,846	
Variable rate loans and borrowings	14,211,247	14,211,247		14,211,247	4,810,340	4,810,340	4,810,340	
Finance lease payables	2,174,537	2,174,537		2,174,537	949,505	949,505	949,505	
Other financial liabilities	30,263,666	30,263,666		30,263,666	1,001,853	1,001,853	1,001,853	
Trade and other payables								
Suppliers				0	33,751,144	33,751,144	33,751,144	
Suppliers, Group companies				0	8,928,909	8,928,909	8,928,909	
Other payables				0	10,156,817	10,156,817	10,156,817	
Total	456,185,860	456,185,860	0	456,185,860	289,979,414	289,979,414	289,979,414	
Total financial liabilities	456,185,860	456,185,860	0	456,185,860	289,979,414	289,979,414	289,979,414	

This appendix forms an integral part of note 20 to the annual accounts, in conjunction with which it should be read

APPENDIX VI 2 of 2

#### GRIFOLS, S.A.

#### Details of Financial Liabilities by Category for the year ended 31 December 2013 (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

		Non-curr	ent			Current		
	At amortised co	st or cost			At amortised cos	st or cost		
	Carrying amount	Fair value	At fair value	Total	Carrying amount	Fair value	Total	
Other liabilities at fair value through profit or loss								
Derivative financial instruments (note 15)			7,563,959	7,563,959			0	
Total	0	0	7,563,959	7,563,959	0	0	0	
Debts and payables								
Loans, Group companies	86,201,597	86,201,597		86,201,597	219,195,997	219,195,997	219,195,997	
Variable rate loans and borrowings	332,229,183	332,229,183		332,229,183	37,630,146	37,630,146	37,630,146	
Finance lease payables	1,453,878	1,453,878		1,453,878	946,209	946,209	946,209	
Other financial liabilities	28,994,025	28,994,025		28,994,025	846,517	846,517	846,517	
Trade and other payables								
Suppliers				0	42,907,308	42,907,308	42,907,308	
Suppliers, Group companies				0	8,082,603	8,082,603	8,082,603	
Other payables				0	7,721,943	7,721,943	7,721,943	
Total	448,878,683	448,878,683	0	448,878,683	317,330,723	317,330,723	317,330,723	
Total financial liabilities	448,878,683	448,878,683	7,563,959	456,442,642	317,330,723	317,330,723	317,330,723	

This appendix forms an integral part of note 20 to the annual accounts, in conjunction with which it should be read

#### Classification of Financial Liabilities by Maturity for the year ended 31 December 2014 (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

			Euros				
	2015	2016	2017	2018	Subsequent years	Less current portion	Total
Payables							
Loans and borrowings	4,810,340	3,126,619	2,618,543	2,268,827	6,197,258	(4,810,340)	14,211,247
Finance lease payables	949,505	736,575	651,354	501,881	284,727	(949,505)	2,174,537
Derivative financial instruments			0	0		0	0
Other financial liabilities	1,001,853	29,344,155	591,973	252,767	74,770	(1,001,853)	30,263,666
Trade and other payables							
Suppliers	24,983,426					(24,983,426)	0
Suppliers, Group companies	8,928,909					(8,928,909)	0
Suppliers, related parties	8,767,718					(8,767,718)	0
Personnel	10,156,817					(10,156,817)	0
Total financial liabilities	59,598,568	33,207,349	3,861,870	3,023,475	6,556,755	(59,598,568)	46,649,449

This appendix forms an integral part of note 21 to the annual accounts, in conjunction with which it should be read

#### Classification of Financial Liabilities by Maturity for the year ended 31 December 2013 (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

			Euros				
	2014	2015	2016	2017	Subsequent years	Less current portion	Total
Payables							
Loans and borrowings	37,630,146	110,046,410	38,218,324	182,659,787	1,304,661	(37,630,146)	332,229,183
Finance lease payables	946,209	531,339	284,870	270,115	367,553	(946,209)	1,453,878
Derivative financial instruments			4,024,954	3,539,005		0	7,563,959
Other financial liabilities	846,517	528,182	23,025,257	270,115	5,170,471	(846,517)	28,994,026
Trade and other payables							
Suppliers	36,238,821					(36,238,821)	0
Suppliers, Group companies	8,082,603					(8,082,603)	0
Suppliers, related parties	6,668,487					(6,668,487)	0
Personnel	7,721,943					(7,721,943)	0
Total financial liabilities	98,134,726	111,105,931	65,553,404	186,739,023	6,842,686	(98,134,726)	370,241,045

Este anexo forma parte integrante de la nota 21 de la memoria de las cuentas anuales, junto con la cual debe ser leido.

#### Main characteristics of payables for the year ended 31 December 2014 (Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

Loan	Currency	cy Interest rate	Grant date	Maturity	Euros			
					Amount extended	Total value	Carrying amount Current	Non-current
Group								
Credit Grifols World Wide Operations Ltd. (Note 21)	EUR	5,25% (Group Senior debt interest rate + 0,75%) 5,25% (Group Senior debt	27/02/2014	27/02/2024	1,000,000,000	378,136,055		378,136,055
Cash pooling (Note 21)	EUR	interest rate + 0,75%) 5,25% (Group Senior debt		2015		199,622,090	199,622,090	
Cash pooling (Note 21)	EUR	interest rate + 0,75%)		2016		29,610,743		29,610,743
Associates					1,000,000,000	607,368,888	199,622,090	407,746,798
Cash pooling (Note 21)	EUR	5,25% (Group Senior debt interest rate + 0,75%)		2015		3,059,403	3,059,403	
Unrelated parties								
Banco Santander	EUR	ICO+1,89	01/06/2009	25/06/2016	6,000,000	1,800,000	1,200,000	600,000
Banca March	EUR	Euribor + 4%	10/07/2013	01/08/2018	6,500,000	6,125,798	1,539,551	4,586,247
Bankinter	EUR	2,25% (to 2018)	21/11/2014	30/09/2024	10,000,000	9,925,613	900,613	9,025,000
Credit facilities	EUR	2,25% -4,75%	20	015 -2016	43,000,000	1,170,175	1,170,175	
				-	65,500,000	19,021,586	4,810,340	14,211,247
				-	1,065,500,000	629,449,877	207,491,833	421,958,045

This appendix forms an integral part of note 21 to the annual accounts, in conjunction with which it should be read

#### Main characteristics of payables for the year ended 31 December 2013 (Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

Loan	Currency	y Interest rate	Grant date	Maturity	Euros			
					Amount extended	Total value	Carrying amount Current	Non-current
Group								
Credit Grifols Inc. (note 21)	USD	0.24%	11/03/2013	11/03/2016	86,201,597	86,201,597		86,201,597
Credit Grifols Inc. (note 21)	USD	0.21%	03/06/2013	03/06/2016	46,053,256	46,053,256	46,053,256	
Cash pooling (note 21)	EUR	Euribor + 1%		2014		132,051,579	132,051,579	
Associates					132,254,853	264,306,432	178,104,835	86,201,597
Cash pooling (note 21)	EUR	Euribor + 1%		2014		2,682,917	2,682,917	
Unrelated parties								
Senior debt Tranche A	EUR	Euribor + 3,5%	(*) 23/11/2010	01/06/2016	220,000,000	172,967,265	32,431,362	140,535,903
Senior debt Tranche B	EUR	Euribor + 3,5%	(*) 23/11/2010	01/06/2017	220,000,000	186,699,029	1,905,093	184,793,936
Total Senior debt					440,000,000	359,666,294	34,336,455	325,329,839
Revolving Credit	EUR	Euribor + 3,25%	(*) 23/11/2010	01/06/2016	21,666,667	(1,026,514)		(1,026,514)
Banco Santander	EUR	ICO+1,89	01/06/2009	25/06/2016	6,000,000	3,000,000	1,200,000	1,800,000
Banca March	EUR	Euribor + 4%	10/07/2013	01/08/2018	6,500,000	6,500,000	374,142	6,125,858
Credit facilities	EUR -USD	2,129% -4,8 %		2014	103,000,000	1,719,549	1,719,549	
					577,166,667	369,859,329	37,630,146	332,229,183
					709,421,520	636,848,678	218,417,898	418,430,780

(\*) Refinanced on 29 February 2012 (see note 21)

This appendix forms an integral part of note 21 to the annual accounts, in conjunction with which it should be read

APPENDIX IX 1 of 2

### GRIFOLS, S.A.

# Reconciliation between net income and expense for the year and the tax loss for the year ended 31 December 2014

(Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Income statement			Income and expense recognised in equity			
	Increases	Decreases	Net	Increases	Decreases	Net	Total
Income and expenses for the period			205,197,369	333,033	(1,289,879)	(956,846)	204,240,523
Income tax Income tax, prior years			(30,268,424) 363,222	(99,910)	381,661	281,751	(29,986,673) 363,222
Profit before income tax Permanent differences			175,292,167	233,123	(908,218)	(675,095)	174,617,072
Individual company	5,005,913	232,996,017	(227,990,104)			0	(227,990,104)
Tax consolidation adjustments		42,244,507	(42,244,507)			0	(42,244,507)
Temporary differences Individual company							
Deferred tax assets not recognised			0				
originating in current year	1,455,313	0	1,455,313	(233,123)	908,218	675,095	2,130,408
originating in prior years	1,258,050	0	1,258,050			0	1,258,050
Tax loss			(92,229,080)			0	(92,229,080)

APPENDIX IX 2 of 2

### GRIFOLS, S.A.

# Reconciliation between net income and expense for the year and the tax loss for the year ended 31 December 2013

(Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Income statement			Income and expense recognised in equity			
	Increases	Decreases	Net	Increases	Decreases	Net	Total
Income and expenses for the period			168,350,884	1,175,517	725,708	1,901,225	170,252,109
Income tax Income tax, prior years			(17,074,997) (318,411)	503,793	311,018	814,811	(16,260,186) (318,411)
Profit before income tax Permanent differences			150,957,476	1,679,310	1,036,726	2,716,036	153,673,512
Individual company	4,108,425	28,124,857	(24,016,432)			0	(24,016,432)
Tax consolidation adjustments	5,032,437	194,567,706	(189,535,269)			0	(189,535,269)
Temporary differences Individual company							
Deferred tax assets not recognised	3,027,716		3,027,716				3,027,716
originating in current year	1,273,026		1,273,026	(1,679,310)	(1,036,726)	(2,716,036)	(1,443,010)
originating in prior years	2,132,139	9,091,691	(6,959,551)			0	(6,959,551)
Tax loss			(65,253,035)			0	(65,253,035)

# APPENDIX X GRIFOLS, S.A.

### Details of income tax expenses/(tax income) related to profit/(loss) for the year ended 31 December 2014

### (Expressed in Euros)

### (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Profit and loss	Equity	Total
Income and expenses for the period before tax	175,292,167	(675,095)	174,617,072
Tax at 30%	52,587,650	(202,529)	52,385,122
Dividends	(12,505,506)		(12,505,506)
Dividends double taxation (exemption)	(69,000,000)		(69,000,000)
Non-deductible expenses			
Donations	1,498,766		1,498,766
Cost of reducing deferred tax assets recognised in prior years	(898,805)		(898,805)
Cost of reducing deferred tax assets not recognised in prior years			0
Charge to the provision for investments	(167,846)		(167,846)
Penalties and fines	3,008		3,008
Tax deductible expenses			
Deductions and credits for the current year	(1,748,561)		(1,748,561)
Adjustment for prior years	363,222		363,222
Adjustment for tax rate	(37,130)		(37,130)
Taxable income/(tax loss)	(29,905,201)	(202,529)	(30,107,730)

# APPENDIX X GRIFOLS, S.A.

## Details of income tax expenses/(tax income) related to profit/(loss) for the year ended 31 December 2013

(Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Euros		
	Profit and loss	Equity	Total
Income and expenses for the period before tax	150,957,476	2,716,036	153,673,512
Tax at 30%	45,287,243	814,811	46,102,054
Non-taxable income			
Dividends double taxation (exemption)	(8,437,457)		(8,437,457)
Non-deductible expenses			
Donations	1,385,168		1,385,168
Cost of reducing deferred tax assets recognised in prior year	2,410,984		2,410,984
Cost of reducing deferred tax assets not recognised in prior	908,315		908,315
Charge to the provision for investments	1,509,731		1,509,731
Penalties and fines	20,211		20,211
Tax deductible expenses			
Capital increase	(172,851)		(172,851)
Deductions and credits for the current year	(1,616,029)		(1,616,029)
Adjustment for prior years	(318,411)		(318,411)
Taxable income/(tax loss)	(17,393,408)	814,811	(16,578,598)

#### GRIFOLS, S,A, Related Party Transactions for the year ended 31 December 2014 (Expressed in Euros)

(Free translation from the original in Spanish, In the event of discrepancy, the Spanish-language version prevails,)

		Euros		
	Group		Other related	
	companies	Directors	parties	Total
Non-current investments in Group companies				
Equity instruments (note 12)	1,641,831,810			1,641,831,810
Loans to companies	16,410,455			16,410,455
Deposits and guarantees Investments in related companies			624,068	624,068
Other investments			3,294,622	3,294,622
Total non-current assets	1,658,242,265	0	3,918,689	1,662,160,954
Trade and other receivables				
Trade receivables – current	32,517,642		-	32,517,642
Current investments in Group companies				
Loans to companies	222,110,583			222,110,583
Total current assets	254,628,225	0	0	254,628,225
Total assets	1,916,165,112	0	3,918,689	1,916,789,179
Non-current payables to Group companies	409,536,410		_	409,536,410
Total non-current liabilities	409,536,410	0	0	409,536,410
Current payables to Group companies Trade and other payables (note 21)	230,380,846			230,380,846
Suppliers	-	600,000	8,167,718	8,767,718
Suppliers, Group companies and associates	8,928,909			8,928,909
Total current liabilities	239,309,755	600,000	8,167,718	248,077,473
Total liabilities	648,846,165	600,000	8,167,718	657,613,883

# GRIFOLS, S.A. **Related Party Transactions** for the year ended 31 December 2013

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

		Euros		
	Group companies	Directors	Other related parties	Total
Non-current investments in Group companies				
Equity instruments (note 12)	1,311,316,684			1,311,316,684
Loans to companies	18,158,520			18,158,520
Deposits and guarantees			811,793	811,793
Investments in related companies Other investments			2,900,442	2,900,442
Total non-current assets	1,332,375,646	0	3,712,235	1,333,187,439
Trade and other receivables				
Trade receivables – current	11,925,808			11,925,808
Current investments in Group companies				
Loans to companies	538,787,936			538,787,936
Total current assets	550,713,744	0	0	550,713,744
Total assets	1,883,089,390	0	3,712,235	1,883,901,183
Non-current payables to Group companies	86,201,597			86,201,597
Total non-current liabilities	86,201,597	0	0	86,201,597
Current payables to Group companies Trade and other payables (note 21)	219,195,998			219,195,998
Suppliers		400,000	6,268,487	6,668,487
Suppliers, Group companies and associates	8,082,604			8,082,604
Total current liabilities	227,278,602	400,000	6,268,487	233,947,089
Total liabilities	313,480,199	400,000	6,268,487	320,148,686

# **Related Party Transactions** for the year ended 31 December 2014 (Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Euros				
	Group	Key management personnel	Directors	Other related parties	Total
Income					
Operating lease income	13,284,373				13,284,373
Other services rendered	72,661,736				72,661,736
Royalties					0
Finance income	13,309,791				13,309,791
Dividends	271,685,018				271,685,018
Total income	370,940,918	0	0	0	370,940,918
Expenses					0
Operating lease expenses	4,360,576			3,991,919	8,352,495
Contributions to foundations				4,261,748	4,261,748
Expenses for licences				3,470,547	3,470,547
Other services received	5,834,866		750,000	1,093,482	7,678,348
Personnel expenses (note 25)		5,585,932	3,881,024		9,466,956
Finance costs	27,445,636				27,445,636
Total Expenses	37,641,078	5,585,932	4,631,024	12,817,697	60,675,730
Investments					
Cost of assets acquired					
Buildings and other installations	550,070				550,070
Total investments	550,070	0	0	0	550,070

# Related Party Transactions for the year ended 31 December 2013 (Expressed in Euros)

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

			Euros		
	Group companies	Key management personnel	Directors	Other related parties	Total
Income	10 000 101				10,000,101
Operating lease income	13,296,104				13,296,104
Other services rendered	64,210,629				64,210,629
Royalties	5,562,054				5,562,054
Finance income	4,387,719				4,387,719
Dividends	222,692,563				222,692,563
Total income	310,149,069	0	0	0	310,149,069
Expenses					0
Operating lease expenses	4,423,610			3,965,906	8,389,516
Contributions to foundations				3,839,128	3,839,128
Expenses for licences				1,859,033	1,859,033
Other services received	5,795,525		700,000	1,268,710	7,764,235
Personnel expenses (note 25)		5,103,669	3,704,779		8,808,448
Finance costs	749,465				749,465
Total Expenses	10,968,600	5,103,669	4,404,779	10,932,776	31,409,824
Investments					
Cost of assets acquired					
Buildings and other installations	557,154				557,154
Total investments	557,154	0	0	0	557,154

# Details of Revenues by Category of Activity and Geographical Market for the years ended 31 December 2014 and 2013 (Expressed in Euros) (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

	Euros									
	Domestic		Rest of Europear	n Union	United Stat	es	Rest of the w	orld	Total	
	2014	2013	2014	2013	2014	2013	2014	2013	2014	2013
Revenue from the rendering of service	39,432,193	39,621,846	16,896,434	3,113,542	19,894,441	23,091,005	1,108,498	904,736	77,331,566	66,731,129
Lease income	13,284,373	13,296,104							13,284,373	13,296,104
Royalties						5,562,054			0	5,562,054
Finance income	5,573,177	3,785,996	925,291	518,424	6,305,156		506,167	83,299	13,309,791	4,387,719
Dividends	41,685,018	194,567,706	230,000,000	20,500,000				7,624,857	271,685,018	222,692,563
	99,974,761	251,271,652	247,821,725	24,131,966	26,199,597	28,653,059	1,614,665	8,612,892	375,610,748	312,669,569

# GRIFOLS, S.A. Statement of Liquidity for Distribution of Interim Dividend 2014 (Expressed in Euros)

	Euros
Forecast profits distributable for 2014: Projected profits net of taxes until 31/12/2014 Less, charge required to legal reserve	211,556,000 0
Estimated profits distributable for 2014	211,556,000
Dividendos a cuenta distribuidos	85,944,364
Forecast cash for the period 2 October 2014 to 20 October 2015: Cash balances at 20 October 2014 Projected amounts collected Projected payments, including interim dividend	67,048,000 508,971,000 383,137,000
Projected cash balances at 20 Octubre 2015	192,882,000

# Details and movements of Class A and B treasury stock for the year ended 31 December 2014 (Expressed in Euros)

	Number of	
	Class A shares	Euros
Balance at 1 January 2014	0	0
Acquisitions of Class A shares	1,967,265	69,134,763
Disposals of Class A shares		
Balance at 31 December 2014	1,967,265	69,134,763

	Number of	
	Class B shares	Euros
Balance at 1 January 2014	653	0
Acquisitions of Class B shares	5,000	117,680
Disposals of Class B shares		
Balance at 31 December 2014	5,653	117,680

# Details and movements of Class A and B treasury stock for the year ended 31 December 2013 (Expressed in Euros)

	Number of		
	Class A shares Euros		
Balance at 1 January 2013	158,326	3,058	
Acquisitions of Class A shares	448,802	11,040	
Disposals of Class A shares	(607,128)	(14,098)	
Balance at 31 December 2013	0	0	

	Number of	
	Class B shares	Euros
Balance at 1 January 2013	16,082	2,124
Cash acquisitions of Class B shares	6,177,372	127,787,825
Non Cash acquisitions of Class B shares	884,997	17,744,190
Cash disposals of Class B shares	(5,307,804)	(107,328,818)
Non Cash disposals of Class B shares	(1,769,994)	(38,205,321)
Balance at 31 December 2013	653	0

### **Directors' Report**

### 2014

(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)

To the Shareholders:

1. Business performance and position of the Company

Grifols, S.A. is a Spanish holding company specialising in the pharmaceutical-clinical sector. It is the Parent of the Grifols Group and its principal activities are as follows:

- Defining action plans and general procedures for the entire Group.
- Planning future investments by entering new markets or through product diversification.

- Providing support to the various functional areas in each Group company (products division, technical division, marketing/sales division, scientific division, financial division and planning and control division).

- Leasing buildings to Group companies.

- Rendering services to subsidiaries such as personnel recruitment and management, communications and corporate image, IT services and maintenance.

The Company obtains its income from leasing its buildings and rendering services, and through dividends from its subsidiaries.

#### 2. Forecast

The Company's profits could be affected by events relating to the activities of its subsidiaries, such as a lack of raw materials for product manufacturing, the arrival of competitor products on the market or regulatory changes in the markets in which it operates.

At the date of authorisation for issue of these annual accounts, the Company has taken the measures it considers appropriate to mitigate any possible effects arising from the aforementioned events.

#### 3. Treasury stock

At 31 December 2014, the Company has treasury stock of Euros 69,252,443, as described in note 18 to the accompanying annual accounts. Transactions involving treasury stock in 2014 are described in note 18 to the accompanying annual accounts.

#### 4. Research and development

The Company does not conduct any research and development activities.

#### 5. Management of financial risks

The Company's financial risk management policy is detailed in note 11 to the accompanying annual accounts.

#### 6. Average payment period

As mentioned in note 22 to the annual accounts, the average payment period is longer than the maximum period stipulated in late payment legislation. The Company is evaluating the most appropriate measures to reduce the average number of days.

#### 7. Events After the Reporting Period

The Company has repurchased industrial assets in Spain for a total amount of Euros 44 million. The Company has exercised the options to purchase assets at fair value included in the corresponding sale and leaseback agreements (see note 7).

The Annual Corporate Governance Report, which is required of listed companies, is included separately to this Directors' Report, of which it forms part.

At their meeting held on 20 February 2015, pursuant to the requirements of article 253.2 of the Revised Spanish Companies Act and article 37 of the Spanish Code of Commerce, the Directors of Grifols, S.A. authorised for issue the annual accounts and directors' report for the period from 1 January 2014 to 31 December 2014. The annual accounts comprise the documents that precede this certification.

Signed:

Victor Grifols Roura (signed) Chairman	Ramón Riera Roca (signed) Board member	Juan Ignacio Twose Roura (signed) Board member
Tomás Dagá Gelabert (signed) Board member	Thortol Holding B.V. (J.A. Grifols G.) (signed) Board member	Thomas Glanzmann (signed) Board member
Edgar Dalzell Jannotta (signed) Board member	Anna Veiga Lluch (signed) Board member	Luis Isasi Fernández de Bobadilla (signed) Board member
Steven F. Mayer (signed) Board member	W. Brett Ingersoll (signed) Board member	Belen Villaronga Morenés (signed) Board member
Marla E. Salmon (signed) Board Member	Raimon Grifols Roura (signed) Secretary to the board	